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Abstract
Identifying disease-gene associations can help improve the understanding of disease mechanisms, which
has a variety of applications, such as early diagnosis and drug development. Although experimental tech-
niques, such as linkage analysis, genome-wide association studies (GWAS), have identified a large number
of associations, identifying disease genes is still challenging since experimental methods are usually time-
consuming and expensive. To solve these issues, computational methods are proposed to predict disease-gene
associations.
Based on the characteristics of existing computational algorithms in the literature, we can roughly divide
them into three categories: network-based methods, machine learning-based methods, and other methods.
No matter what models are used to predict disease genes, the proper integration of multi-level biological
data is the key to improving prediction accuracy. This thesis addresses some limitations of the existing
computational algorithms, and integrates multi-level data via artificial intelligence techniques. The thesis
starts with a comprehensive review of computational methods, databases, and evaluation methods used in
predicting disease-gene associations, followed by one network-based method and four machine learning-based
methods.
The first chapter introduces the background information, objectives of the studies and structure of the
thesis. After that, a comprehensive review is provided in the second chapter to discuss the existing algorithms
as well as the databases and evaluation methods used in existing studies. Having the objectives and future
directions, the thesis then presents five computational methods for predicting disease-gene associations.
The first method proposed in Chapter 3 considers the issue of non-disease gene selection. A shortest
path-based strategy is used to select reliable non-disease genes from a disease gene network and a differential
network. The selected genes are then used by a network-energy model to improve its performance. The
second method proposed in Chapter 4 constructs sample-based networks for case samples and uses them to
predict disease genes. This strategy improves the quality of protein-protein interaction (PPI) networks, which
further improves the prediction accuracy. Chapter 5 presents a generic model which applies multimodal deep
belief nets (DBN) to fuse different types of data. Network embeddings extracted from PPI networks and gene
ontology (GO) data are fused with the multimodal DBN to obtain cross-modality representations. Chapter
6 presents another deep learning model which uses a convolutional neural network (CNN) to integrate gene
similarities with other types of data. Finally, the fifth method proposed in Chapter 7 is a nonnegative
matrix factorization (NMF)-based method. This method maps diseases and genes onto a lower-dimensional
manifold, and the geodesic distance between diseases and genes are used to predict their associations. The
method can predict disease genes even if the disease under consideration has no known associated genes.
In summary, this thesis has proposed several artificial intelligence-based computational algorithms to
address the typical issues existing in computational algorithms. Experimental results have shown that the
proposed methods can improve the accuracy of disease-gene prediction.
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1Introduction
1.1 Background
Complex diseases are caused by the malfunctioning of a group of genes, known as disease-associated genes, or
simply disease genes. Identifying these genes is critical for scientists to decipher the mechanism of diseases,
which is beneficial to disease diagnosis and drug development [1]. However, this issue is still challenging
since experimentally identifying disease genes is time-consuming and expensive. On the one hand, scientists
need to conduct a few experiments to determine whether a gene is disease-associated, which might require
years of efforts [2]. On the other hand, experimental techniques such as genome-wide association studies
(GWAS) usually identify hundreds of candidates, and scientists have to determine the priority of validations
to maximize the yield of their experiments. Therefore, computational methods which prioritize disease genes
are valuable for disease-gene identification.
Currently, many algorithms have been proposed to predict disease genes. Despite their success, different
methods all have their pros and cons. Artificial Intelligence (AI) tries to harness the power of techniques
like machine learning and deep learning to solve problems by analyzing and learning from vast datasets at
speeds and capacities not possible for humans alone. Its flexibility in data integration is also valuable for
disease-gene prediction since the key to accurate prediction is to properly fuse multi-levels of biological data.
Thus, this thesis mainly focuses on machine learning-based methods, especially deep learning models, which
can characterize the non-linear relationships among different types of data.
In our studies, we first develop algorithms to solve common issues existing in developing machine learning-
based methods, such as the selection of negative data and the quality control of protein-protein interaction
(PPI) networks. Then, several deep learning models are applied to fuse multi-level of biological data and
extract cross-modality features. These features characterize both linear and non-linear relationships among
different modalities, which could advance the prediction of disease-gene associations.
1.2 Motivations and objectives
The overall objective of our studies is to combine multiple types of data with deep learning models to
improve the accuracy of disease-gene prediction. Before applying deep learning models to this area, a few
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issues should be addressed.
First, considering that we use supervised models to predict disease-gene associations, both positive and
negative instances are required to train the models. However, disease-gene prediction is a positive-unlabeled
learning problem, in which only positive instances (disease genes) are available [3]. A set of negative instances
(non-disease genes) have to be defined before training the models. Thus, developing a strategy to select
negative data is fundamental to our research.
Second, PPI networks are widely used in existing algorithms since they reveal the functional similarities
of proteins, which are critical for disease-gene prediction. However, PPI networks obtained from online
databases contain many false positives and false negatives [4], and directly using them in the algorithm
would limit the accuracy of the prediction. Meanwhile, protein interactions are tissue-specific and dynamic,
universal static networks downloaded from public databases cannot reveal true protein interactions in the
samples. Therefore, a strategy should be developed to purify the static PPI networks and improve their
quality.
After solving these two issues, the next step is to properly fuse multiple types of data to achieve accurate
prediction. Specifically, deep learning models which use nonlinear activation functions are applied in our
studies to capture the nonlinear relationships among various types of data. Multimodal deep belief nets
(DBNs), a fundamental deep learning architecture which has been successfully applied to fuse image and
text data [5], is first applied to learn latent representations from different types of biological data. In addition,
convolutional neural networks (CNNs), which use the same filter for similar inputs, could also be applied for
representation learning since they allow to leverage the functional similarities of genes.
Finally, since most supervised algorithms require known disease genes as positive data to train the model,
they cannot be applied to diseases with only a few associated genes or no known disease genes. However, the
nonnegative matrix factorization (NMF)-based methods are not limited by this problem, and a few NMF-
based models have successfully been used to predict disease genes [6, 7]. Unfortunately, existing methods still
perform badly for diseases with no known associated gene. A better method should be proposed to improve
their accuracy. In the meantime, it is interesting to compare NMF-based methods with deep learning-based
methods to find out their specialties.
Based on these motivations, this study has the following objectives:
Objective 1: Review existing computational algorithms for predicting disease-gene associations.
Objective 2: Develop a new strategy to select non-disease genes and combine it with network energy-
based model to predict disease genes.
Objective 3: Develop a method to improve the quality of PPI networks and apply it to predict disease
genes.
Objective 4: Use a multimodal DBN to integrate different types of data and extract cross-modality
features to predict disease genes.
Objective 5: Apply the CNN model to integrate different types of data based on gene similarities.
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Objective 6: Present an NMF-based method which can accurately predict disease genes for diseases
both with many known associated genes and no known associated genes. Then compare it with the deep
learning-based methods.
1.3 Organization of the thesis
This is a manuscript-style thesis. The main content is presented in the form of published or submitted
manuscripts that I have written during my Ph.D. study. An introduction is given at the beginning of each
chapter to describe the connection of the manuscript to the context of the thesis. All manuscripts have been
reformatted to maintain consistency. The reference lists of all publications have been unified, and there is
only one bibliography at the end of the thesis.
The remainder of the thesis is organized as follows. Chapter 2 reviews the existing computational
methods, databases, and evaluation methods used in disease-gene prediction. Chapter 3 proposes a method
to select non-disease genes from OMIM data and clinical expression data and combines it with network
energy-based model to predict disease genes. Chapter 4 proposes a strategy to improve the quality of
PPI networks by constructing sample-based networks and use them with an ensemble strategy to predict
disease genes. Chapter 5 presents a deep learning-based algorithm which applies multimodal DBN to predict
disease genes. Chapter 6 proposes another deep learning-based method which uses CNN model to leverage
functional similarity data. Chapter 7 presents an NMF-based method which uses manifold learning to predict
disease genes. Prior information is added to the association matrix to improve the accuracy of the algorithm
in predicting associated genes for diseases with no known disease genes. Finally, Chapter 8 summarizes
the work presented in this thesis and discusses several future directions for this research. The copyright
permissions of the manuscripts are included in Appendix B.
3
2Predicting disease-associated genes: computational methods, databases,
and evaluations
Prepared as: Ping Luo, Bo-Lin Chen, Bo Liao, and Fang-Xiang Wu. Predicting disease-associated genes:
computational methods, databases, and evaluations. WIREs: Data Mining and Knowledge Discovery, under
revision, 2019. PL reviewed the existing literature, and FXW supervised the study. PL and FXW wrote the
manuscript. All authors read, revised and approved the final version of the manuscript.
This chapter presents a literature review about computational algorithms, databases and evaluation
methods used in predicting disease genes. The review classifies existing algorithms into three categories:
network-based methods, machine learning-based methods and other methods. The pros and cons of different
types of methods are discussed, as well as several perspectives to improve them. Commonly used databases
and evaluation methods are also discussed so that researchers can easily develop their own algorithms.
Objective 1 of the thesis is fulfilled in this chapter.
Abstract
Complex diseases are associated with a set of genes (called disease genes), the identification of which can
help scientists uncover the mechanisms of diseases and develop new drugs and treatment strategies. Due
to the huge cost and time of experimental identification techniques, many computational algorithms have
been proposed to predict disease genes. Although several review publications in recent years have discussed
many computational methods, some of them focus on cancer driver genes while others focus on biomolecular
networks, which only cover a specific aspect of existing methods. In this review, we summarize existing
methods and classify them into three categories based on their characteristics. Then, the state-of-the-art
algorithms, biological data and evaluation methods used in the computational prediction are discussed.
Finally, we highlight the limitations of existing methods and point out some future directions for improving
these algorithms. This review could help investigators understand the principles of existing methods, and
thus develop new methods to advance the computational prediction of disease genes.
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2.1 Introduction
Deciphering the associations between diseases and genes is critical for us to understand the modular nature
of complex diseases, which has many applications, such as diagnosis, treatment, and prevention of diseases.
Usually, genes whose malfunctioning causes diseases are known as disease-associated genes, or simply disease
genes. A few experimental techniques can be used to identify these genes, such as linkage analysis [8],
genome-wide associations studies (GWAS) [9], and RNA interference (RNAi) [10]. Among these techniques,
linkage analysis and GWAS are most frequently used. The former is successful in identifying genes associated
with Mendelian diseases (single gene diseases), while the latter is superior to the former in predicting genes
associated with complex diseases (non-Mendelian diseases) [11]. Despite their achievements, these techniques
usually select genetic loci corresponding to hundreds of candidate genes, whose further validation is time-
consuming and expensive. Thus, many computational algorithms have been proposed to predict or prioritize
disease genes so that scientists can optimize the in-depth experimental validation and maximize the yield of
their experiments.
An intuitive strategy for computational methods is to analyze the results of GWAS and predict disease
genes from the previously mentioned hundreds of candidates. This results in a group of post-GWAS analysis
algorithms. However, not all disease-associated variants can be identified by GWAS [12], and GWAS data are
not always available for all kinds of diseases. Thus, computational methods have also used many other types
of data, such as protein-protein interaction (PPI) networks, gene expression profiles, pathways, gene ontology
(GO) terms, to predict disease genes. The authors of [2] have classified various existing types of data into
five categories. Among them, the mutation data are most promising. Newly developed algorithms for cancer
driver gene prediction also tend to focus on analyzing somatic mutations rather than other types of data.
Unfortunately, large scale mutation data are usually unavailable for diseases other than cancer. Therefore,
in this review, we focus on computational algorithms and data sources that can be used to predict associated
genes for all kinds of diseases. Algorithms specifically designed for predicting cancer driver genes can be
found in [13].
Based on the principles used in the classification, existing methods can be divided into various categories.
In [11], the authors have classified computational methods based on three criteria: “type of evidence”, “scope
of application” and “type of prediction”. With these criteria scientists can quickly find the methods they
need based on their objectives and data at hand. However, methods in each category might vary a lot in
terms of their core models, which is inconvenient for researchers who want to improve current models and
develop new algorithms. In this review, instead of using these criteria, we focus on the characteristics of
computational algorithms and classify them into network-based methods, machine learning-based methods,
and other methods. Figure 2.1 shows the details of the classification. We believe that such a classification
can help researchers capture the core ideas behind existing algorithms, which might assist them in developing
new effective algorithms.
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Figure 2.1: Classification of existing computational methods for disease gene prediction.
In the rest of this review, we first discuss existing computational disease gene prediction methods. Then,
a few types of frequently used data are described in Section 2.3, as well as the strategies developed for
analyzing them. After that, Section 2.4 introduces some evaluation methods. Finally, we conclude with
a discussion of the limitations of existing methods and perspectives for developing new algorithms in the
future.
2.2 Computational methods
2.2.1 Network-based methods
Based on the ‘guilt by association’ assumption, genes associated with each other may have similar func-
tions [14]. Therefore, various types of biomolecular networks which characterize associations among genes
have been used to predict disease genes. Very briefly, network-based algorithms can be divided into four
groups: distance-based methods, random walk-based methods, network energy-based methods, and network
centrality-based methods.
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Distance-based methods
Distance-based methods were the first to be developed to predict disease genes. These methods use the
length of the shortest path (distance) in biomolecular networks to determine if a gene is disease-associated.
Unknown genes (genes that have not been identified as being associated with a certain disease) with a
distance smaller than a threshold are predicted as disease-associated. For instance, George et al. developed
a method known as CPS which predicted a gene as disease-associated if it was in a disease-related pathway
and close to the known disease genes [15]. Snel et al. combined PPI network with disease-associated loci to
predict a gene as disease-associated if it was located within these loci, and its neighbors contained known
disease genes [16]. Franke et al. used the distance to calculate similarity scores with the Gaussian kernel,
and unknown genes with higher similarity scores were predicted as disease-associated [17].
These methods only use local topological structures, and their accuracy is limited. Random walk-based
methods have shown that the global topological structure is more valuable for disease gene prediction than
local information [18]. Nevertheless, the distance-related evidence is still valuable and has been used to
extract features with many machine learning-based methods [19].
Random walk-based methods
To improve the distance-based methods, the random walk is applied to predict disease genes. Even since the
first random walk with restart (RWR) algorithm was proposed in [18], it has become one of the state-of-the-
art algorithms for disease gene prediction. As a kind of information flow-based algorithm, random walk-based
methods propagate the prior information from each node to its nearby nodes in an iterative manner for a
predefined number of steps or until convergence. The final value of a node is influenced by the values of its
direct neighbors, which in turn are affected by their neighbors. This value also represents the probability of
each node being associated with the disease under consideration. Due to its superiority, random walk-based
methods have been applied in many other areas as well, including gene function prediction [20] and drug
target prediction [21].
Given a disease d, let P0 denote the prior information where P0(i) = 1 represents gene i is known to be
associated with d and P0(i) = 0 otherwise. The random walk can be performed by the following equation
Pt+1 = WPt = W
tP0, (t ≥ 0) (2.1)
where W is the column normalized adjacency matrix of the PPI network. If W is a stochastic matrix, this
process is equivalent to a random walk on the network. Furthermore, if we allow the random walk to restart
in every step with a probability r, we can obtain the RWR algorithm as follows:
Pt+1 = (1− r)WPt + rP0 (2.2)
where Pt in the steady state would contain the probability of each gene being disease-associated.
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Figure 2.2: Schematic example of a random walk. The network contains 50 nodes (genes), in which
15 of them are disease-associated. Their corresponding entries in P0 are equal to 1. The random walk
is performed with a restart probability of r = 0.5, and it reaches a stead state when t = 17.
Figure 2.2 illustrates the process of a random walk which is performed on a randomly generated network
with 50 nodes, 15 of which are disease-associated. With a restart probability r = 0.5, the random walk
reaches the steady state (Pt+1 − Pt < 10−6) after 17 rounds of iterations. From the color of the nodes we
can find that the prior information is propagated to the other 35 nodes during the iteration process.
Ko¨hler et al. first used RWR to predict disease genes in [18]. They also proposed a diffusion kernel
method which was the continuous-time analog of RWR. The diffusion kernel of a network was defined by
K = e−βL, where L = D − A was the Laplacian matrix, D was a diagonal matrix containing the degrees of
the nodes, A was the adjacency matrix of the network. P was then computed by P = KP0.
RWR and diffusion kernel captured the global topological properties of the network and were superior to
the distance-based algorithms. However, Ko¨hler et al. only performed RWR on top of a PPI network, and P0
only contained information of known disease-gene associations. To improve the accuracy of the prediction,
many researchers started to combine RWR with other types of data.
One strategy is to enhance P0 with information obtained from other types of data. For instance, PRINCE
used a logistic function to calculate P0 based on the similarity of diseases [22]. If a gene was associated with
a disease which was similar to the disease under consideration, its prior probability would be close to 1.
Another strategy is to enrich the PPI network with extra information. For instance, Erten et al. and Le et
al. weighted the PPI network with reliabilities calculated from other data sources [23, 24]. Magger et al.
built a tissue-specific network and performed PRINCE on it [25].
These methods improved the accuracy of disease-gene prediction. However, they only used PPI networks.
To further leverage the potential of random walks, researchers begun to use heterogeneous networks to
improve the prediction accuracy.
Heterogeneous networks are networks with multiple types of nodes and edges. The first RWR on het-
erogeneous (RWRH) network algorithm was proposed by Li et al. and the network was constructed by
combining PPI network, disease gene associations and disease similarity network [26]. RWRH performed
much better than the RWR algorithm, and many studies were then conducted to improve it. For instance,
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Luo et al. constructed the heterogeneous network based on a curated PPI network and improved the predic-
tion accuracy [27]. Jiang constructed three disease similarity networks and nine gene similarity networks and
combined them into 27 heterogeneous networks. Then, RWR was applied on these networks respectively,
and a weighted Fisher’s method was used to combine all the propagated values to prioritize disease genes
[28]. Valdeolivas et al. constructed a multiplex heterogeneous network in which the same nodes in different
heterogeneous networks are connected with each other. This strategy allowed the random walk to transit
between different networks, which significantly improved the accuracy of the prediction [29].
Note that heterogeneous networks allow different types of nodes, researchers can also integrate other
omics data to construct the network. For instance, Lei et al. constructed a triple heterogeneous network
by incorporating long non-coding RNA (lncRNA) into the network. Specifically, lncRNA-lncRNA similarity
network, gene-lncRNA associations and lncRNA-disease associations were fused to the traditional heteroge-
neous networks [30].
Network centrality-based methods
Centrality characterizes the importance of nodes and edges in a network, which has been widely used in
social network analysis [31, 32] and essential protein prediction [33, 34, 35]. However, genes that transcribed
to essential proteins are usually not disease-associated [36], and directly applied network centrality to predict
disease genes is difficult.
The most successful centralities used in disease gene prediction are feedback centralities, such as Katz
centrality and PageRank. These centralities of one node depends on the centralities of its neighbors, which
further depends on the centralities of their neighbors. The process of feedback is similar to RWR. In fact,
RWR is also known as personalized PageRank [37]. Therefore, methods that use feedback centrality also use
similar strategies as random walk-based methods to predict disease genes. For instance, Singh-Blom et al.
built a heterogeneous network and used Katz centrality to characterize the possibilities of every disease-gene
pairs being associated [38]. Ganegoda et al. also used Katz centrality in their study [39], except that they
replaced the PPI network by a tissue-specific network.
Centrality-based methods improve the disease-gene prediction to some extent. However, compared to
directly being used to predict disease genes, Centralities are more likely to be used to extract topological
features in machine learning-based methods [38, 40, 41, 42, 43].
Network energy-based methods
The network energy-based method was first proposed in [44]. The authors formulated the disease gene
prediction problem as a network labeling problem in which disease genes were labeled as 1 while non-disease
genes (genes not associated with the disease) were labeled as 0.
Given h genes in a biomolecular network, a set of binary labels x = (x1, x2, . . . , xh) of these genes,
(xi ∈ {0, 1}), is known as a configuration of the biomolecular network, and the set X = {x1,x2, . . . ,x2h} of
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all possible configurations is a random field. The probability of the configuration x of a random field X can
be calculated by the Boltzmann distribution [45]
P (x) =
1
Y
· exp(−κH(x)) (2.3)
where H(x) is the Hamiltonian (energy) of the configuration x, κ is a parameter, and Y is called the partition
function and defined as Y =
∑
x∈X exp(−κH(x)). From this equation we can find that the true configuration
of the network should have the maximum probability and thus the minimum energy.
Let x[−i] be the set of binary labels of all genes except for gene i in the network. Adopting the Ising
model to calculate the Hamiltonian, the following equation can be obtained
P (xi = 1|x[−i], θ˜) = e
α+βNi0+γNi1
eα+βNi0+γNi1 + 1
(2.4)
where θ˜ = (α, β, γ) are model parameters. Ni0 and Ni1 are the numbers of neighbors with labels 0 and 1
of gene i, respectively. Details of the derivation can be found in [46]. Parameter θ˜ can be estimated by
maximizing the posterior distribution of P (x1, . . . , xn|xn+1, . . . , xn+m) where xn+1, . . . , xn+m are the labels
of the m known disease genes. Furthermore, if M networks are available, (2.4) can be generalized as follows
P (xi = 1|x[−i], θ) = exp(V (i))
exp(V (i)) + 1
(2.5)
where
V (i) = α+
M∑
m=1
[βm ·Nmi0 + γm ·Nmi1 ],
µ = (α, βm, γm) (m = 1, . . . ,M) are model parameters. Nmi0 and N
m
i1 are the numbers of neighbors with
labels 0 and 1 of gene i in the m-th network, respectively.
Network energy-based model can be used to integrate multiple biomolecular networks to predict disease
genes. In [46], the authors integrated five biomolecular networks and estimated θ with Gibbs sampling. Later
on, they combined graph kernel with their model and proposed a kernel-based algorithm. This strategy
allowed the algorithm to use the information between genes and their indirect neighbors since kernel brought
similarity information into the network [47]. Having noticed that Eq. (2.4) followed a logistic model where
φi = (1, Ni0, Ni1) was the feature vector and θ˜ was the weight parameter. Parameter θ˜ could be estimated by
a convex optimization problem which was much faster than the original Gibbs-based methods. Ni0 and Ni1
could also be extended to extract more similar features. Thus, Chen et al. proposed a fast algorithm based
on this new strategy and extracted additional features N li0 and N
l
i1 which were the number of the l-order
neighbors of gene i [48]. This algorithm improved their original running time by more than 20 folds and the
performance for more than 10% in terms of the area under the receiver operating characteristic curve.
2.2.2 Machine learning-based methods
Machine learning-based methods formulate disease gene prediction as a binary classification problem where
disease genes are predicted as 1 and non-disease genes are predicted as 0. Based on whether known disease
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genes are used in the prediction, machine learning-based methods can be divided into unsupervised methods
and supervised methods.
Unsupervised methods
Unsupervised methods identify patterns in dataset without knowing the labels of instances. For disease gene
prediction, most unsupervised methods use clustering algorithms to predict disease-associated modules from
biomolecular networks. These modules are subnetworks consisting of genes associated with the diseases.
The first widely used algorithm, Weighted Gene Correlation Network Analysis (WGCNA), used hierarchical
clustering on top of co-expression networks to search disease-associated modules [49]. WGCNA provided
an easy-to-use R package, and many studies have used it to identify disease-associated genes [50, 51]. In
addition to co-expression networks, researchers also combined co-expression and PPI networks to find disease
modules. For instance, Wu et al. weighted a protein functional interaction network with Pearson correlation
coefficient (PCC) and applied Markov clustering on this network to predict disease genes [52]. This method
allowed the clustering algorithm to leverage the topological properties within the PPI networks.
Although successful, these algorithms mainly used co-expression data to find disease-associated modules,
and only a small amount of genes (< 20%) in the detected modules are disease-associated [53]. To improve
the efficiency, differential co-expression (also known as “guilt by rewiring”) [54] was applied to predict disease
modules.
Usually, genes that are differentially co-expressed in different groups of samples are more likely to be
disease-associated [55, 56]. Methods based on this assumption construct differential networks in which edges
are weighted by the variation of co-expression and apply clustering algorithms on these networks to predict
disease genes. For instance, DiffCoEx built an adjacency change matrix based on the co-expression networks
of two conditions (case and control). Then, the topological overlap was used to construct a dissimilarity
network, and hierarchical clustering was used to find out modules that were differentially co-expressed with
the same sets of genes [57]. Another example is EW dmGWAS, which weighted the edges of a PPI network
with differential co-expression and nodes of the network with P -values obtained from GWAS data. A seed-
growth approach was then used to find subnetworks with the locally maximum proportion of low-P -values
and highly rewired edges [58].
Unsupervised methods can be applied to predict disease genes even if a disease has no known associated
genes. Since known disease-gene associations are not used in the prediction, their accuracy is usually worse
than supervised methods. However, unsupervised methods are still widely used in analyzing biological data,
especially gene expression data. One reason is that these algorithms are user-friendly, and do not require
complicated data preprocessing. Another reason is that large numbers of gene expression data are available
for applying unsupervised methods. Biclustering algorithms and differential co-expression analysis have
successfully identified many tissue-specific and cell-type-specific disease-related modules.
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Figure 2.3: Classic pipeline of supervised machine learning-based methods.
Supervised methods
Supervised methods train a classifier/regressor based on the known disease-gene associations. Figure 2.3
shows the pipeline of most supervised methods. First, the features are either extracted from a fused dataset
(e.g. PPI network weighted by gene expression or GWAS data) or concatenated from feature subsets ex-
tracted from each type of data. Then, a classifier/regressor, such as biased SVM, logistic regressor and
random forest, is trained with these features and used for future prediction. Based on the key ideas of
the methods, supervised methods can be further divided to feature-based, deep learning-based and matrix
factorization-based methods.
A. Feature-based
Feature-based methods focus on extracting features which characterize the functional similarities of genes.
Appropriate data integration is necessary for obtaining discriminative features.
As depicted in Figure 2.3, the features can be extracted from fused data or concatenated from individual
features extracted from each type of data. No matter which strategy is chosen, most feature-based methods
linearly combine different types of data. For instance, Wu et al. proposed CIPHER, which extracted shortest-
path based features from a heterogeneous network [19]. ProDiGe used kernels to calculate gene similarities
from each type of data and combined them together by the weighted average of these similarity profiles [3].
PUDI directly concatenated features extracted based on GO, protein domain and a PPI network [41].
Note that PPI networks were used to extract features in these algorithms. However, neither length of the
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shortest path or degree of the node can capture the topological properties of the entire network. To improve
these strategies, researchers started to use multiple types of centralities to extract both local and global
topological properties. For instance, Ramadan et al. extracted 13 topological features, most of which were
centrality indices, and trained a decision tree to predict disease genes [42]. Luo et al. used closeness centrality
and edge clustering coefficient to capture both global and local topological structures from a sample-specific
network [43] 1.
Methods using centrality-based features perform better than earlier developed algorithms; however, cen-
trality indices are not the best approach for learning network representations. Considering that many
algorithms have been developed to learn network embeddings, researchers started to use these algorithms to
extract features for disease gene prediction. For instance, Ata et al. proposed an algorithm (Metagraph+)
which constructed a metagraph by combining PPI networks and keywords that describe the mechanisms of
proteins [59]. In the metagraph, each protein was connected with other proteins and the keywords that de-
scribe itself. A matagraph embedding learning algorithm, SymISO [60], was used to extract representations
for each protein (gene). Moreover, researchers can also concatenate network embeddings with other types of
features to improve prediction accuracy. In [61], Ata et al. proposed N2VKO, which directly extracted fea-
tures from PPI networks by node2vec [62], and concatenated these embeddings with features extracted based
on UniProt annotations. They tested the features with several classifiers and demonstrated that N2VKO
performed better than many classic algorithms, such as RWRH, ProDiGe and Metagraph+.
Note that most algorithms extract features from PPI networks using all the known disease-gene asso-
ciations. However, Know-GENE proposed by Zhou et al. showed that features extracted with a subset of
disease genes were more discriminative than those extracted using all the disease genes [63]. These subset
of genes, defined as “Core genes”, were those residing in the largest interacting cluster formed by all the
disease genes. Researchers could use this strategy when developing new algorithms.
B. Deep learning-based
Similar to feature-based methods, deep learning-based methods also focus on feature extraction. However,
the non-linear activation functions in deep learning models enable an algorithm to learn the non-linear
relationships between different types of data, which is different from traditional feature-based methods. For
instance, Luo et al. proposed a method which used multimodal deep belief net (DBN) to combine features
extracted from different modalities [64] 2. Specifically, raw features learned based on gene ontology and PPI
networks were fused by a multimodal DBN to learn cross-modality representations, which were further used
to predict disease-gene associations. Their evaluation results showed that prediction using cross-modality
features were more accurate than original raw features.
In addition to DBN, convolutional neural network (CNN) was also used to predict disease genes. Different
1[43] is Chapter 4 from this thesis
2[64] is Chapter 5 from this thesis
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from image data, gene-related features do not contain spatial information. However, a model known as graph
CNN can solve this problem. In this model, the convolution is performed by aggregating information from
the neighbors of each node in a graph [65]. This graph can model any biomolecular networks that reveal
the functional similarity of genes. In [66], the authors used graph CNN to learn representations from a
heterogeneous network. Specifically, raw features extracted for diseases and genes were integrated into the
heterogeneous and further learned by graph CNN. Their evaluation results showed that the method performed
much better than most classic algorithms, such as inductive matrix completion (IMC) [6] and Katz [38].
C. Matrix factorization-based
Apart from feature-based methods, nonnegative matrix factorization (NMF) has also been used to predict
disease genes. Unlike most supervised methods, NMF-based methods can predict disease genes even if the
disease under consideration has no known associated genes. Given a disease-gene association matrix A, in
which A(i, j) = 1 if disease i and gene j are associated and A(i, j) = 0 otherwise. The general idea is to
find a low-rank matrix P = WHT , where W ∈ Rm×k and H ∈ Rn×k are of rank k  min(m,n), so that
P ≈ A. This problem can be solved by NMF, and matrix P contains the probabilities of every disease-gene
pairs being associated. During the factorization, additional information can be integrated into the objective
function so that the factorization is in concert with other biological evidence. A typical algorithm was the
IMC proposed by Natarajan and Dhillon. The algorithm leveraged gene-related and disease-related features
during the factorization, making it possible to integrate multiple types of data [6]. Another example was
the probability-based collaborative filtering model (PCFM) proposed by Zeng et al. which used alternating
least squares to solve the factorization [7]. In PCFM, disease similarities and gene similarities were used to
regularize the objective function, which was a common strategy used by many NMF-based studies.
In addition to classic NMF algorithms, manifold learning can also be used in disease gene prediction.
Different from NMF where entries in P denote the probabilities of diseases and genes being associated,
manifold learning mapped the diseases and genes onto a lower dimensional manifold and used the geodesic
distance between diseases and genes to predict their associations [67, 68] 3. Known disease-gene associations
are used in the mapping based on the assumption that distance between a disease and its associated genes
should be shorter than other non-disease genes. Thus, disease-gene pairs with smaller distance on the lower
dimensional manifold are more likely to be associated.
2.2.3 Other methods
Other than the methods discussed in Sections 2.2.2 and 2.2.1, there are also many algorithms that cannot
be classified into the previous two categories. One of them is ensemble-based methods which calculate a
few ranked lists based on different types of data and outputs the final prediction by fusing all the ranked
lists. Different models can be applied when the ranking is calculated on each type of data. A typical
3[68] is Chapter 7 from this thesis
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example is Endeavor, one of the most famous ensemble-based methods, which can analyze 75 data sources
and predict associated genes for six species. During its prediction, rankings obtained from each data source
were combined by order statistics [69, 70]. Another example was DADA, which proposed five statistical
adjustment methods to generate five raw rankings and used the best ranking of each gene as its final ranking
[71].
Another type of method is text-based, which used text mining to analyze existing literature and predict
disease genes. For different methods, the model might be completely different. For instance, DISEASES
calculated a score for each disease-gene pair according to their co-occurrence within the same abstracts and
the same sentences [72]. DigSee extracted ten linguistically motivated features and used a Bayesian classifier
to identify disease-gene association evidence [73, 74]. Although text-based methods cannot provide de novo
prediction (only documented genes can be predicted), their results are useful for disease gene databases, and
many databases have used text-based methods to collect disease-gene associations [72, 75, 76].
2.3 Biological data
As discussed in Introduction, various types of data have been used to predict disease genes. Figure 2.4
shows several types of widely used evidence in existing algorithms. Some of them characterize the functional
similarity of genes, while others directly provide disease-associated information.
2.3.1 Disease-gene associations
The known disease-gene associations are the most significant. These data can be used to predict new disease
genes and evaluate the prediction accuracy. Table 2.1 lists six databases that collect disease-gene associations.
The first five databases (OMIM, DisGeNET, GAD, CTD, and PsyGeNET) contain genes associated with
all kinds of diseases while the last one (COSMIC) mainly collects cancer-associated genes. Among these
databases, OMIM is the most frequently used one in the algorithms we reviewed. However, OMIM focuses
on Mendelian disorders, and genes associated with complex diseases are not comprehensively collected. An
alternative is DisGeNET, which collects disease-gene associations from seven data sources, including CTD
and PsyGeNET. This might be a better choice for studies on complex diseases.
In addition, although many algorithms are not specifically designed for cancer, researchers prefer to use
cancer to validate their methods. One of the reasons is that many wet-lab studies have been conducted on
various types of cancer, which is convenient for de novo validation. Another reason is that different types of
cancer are well studied, and the number of known cancer-related genes is larger than other diseases, which is
beneficial for training the model, especially for supervised learning methods. For methods that use cancer to
evaluate their performance, the Cancer Gene Census project in COSMIC contains the most comprehensive
cancer-related genes. Thus, algorithms should use their association data for the prediction.
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Figure 2.4: Eight types of evidence valuable for disease gene prediction. The five types of evidence
in the left blue circle characterize the functional similarity of genes, and the two types of evidence in
the right yellow circle contain disease-associated information. Gene expression in the middle contain
both types of information.
Non-disease genes
Along with disease-gene associations, many algorithms require non-disease genes to train their models or
evaluate their performance. Unfortunately, no databases contain non-disease genes, and computational
methods have to select a set of unknown genes as non-disease genes. The simplest strategy is to randomly
select a group of unknown genes as non-disease genes. The number of the selected genes varies depending
on the model used for prediction. For weighted models (e.g. biased SVM or weighted random forest), the
number of the non-disease genes is usually five to twenty fold higher than the known disease genes. For other
models, the size of the positive and negative data should be similar to avoid imbalanced samples. Although
the selected genes might be unidentified disease genes, the probability would be small since the number of
all disease genes is much less than that of unknown genes. Furthermore, the bootstrap aggregating which
improves the stability and accuracy of computational prediction [77] can be used by selecting several groups
of non-disease genes and performing the prediction in an ensemble manner.
Additionally, instead of randomly selecting a group of unknown genes, for supervised machine learning-
based methods, a better choice is to first define a set of highly potential non-disease genes [reliable negatives
(RNs)], then select a subset of genes from RN as negatives. For instance, Luo et al. calculated the similarities
of various diseases and used the associated genes of one disease as non-disease genes of the other one for
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Table 2.1: Some commonly used databases of disease-gene associations
Name URL Ref. Latest Update
OMIM https://www.omim.org [80] 01/01/2019
DisGeNET http://www.disgenet.org [81, 76] 01/14/2019
GAD https://geneticassociationdb.nih.gov [82] 08/18/2014
CTD http://ctdbase.org [83] 01/13/2019
PsyGeNET http://www.psygenet.org [84, 85] 09/02/2016
COSMIC https://cancer.sanger.ac.uk [86, 87] 11/13/2018
two dissimilar diseases [78] 4. This strategy collected a set of RN which enabled the training of a successful
model. However, note that the reasons of different genes not associated with a disease are different. Some
of these genes might be passenger genes while others might have completely no function for disease genesis.
A set of well defined non-disease genes might be linearly separable from the disease genes, resulting in high
prediction accuracy. However, this accuracy does not guarantee the successful prediction of all unknown
genes. To solve this issue, Yang et al. proposed a strategy in PUDI which classified unknown genes into
four categories: likely positives, likely negatives, reliable negatives, and weak negatives [41]. This strategy
allowed the model to be trained with different types of unknown genes, which would enhance its ability in
predicting new disease genes.
For network-based and other methods, the artificial linkage interval was frequently used to select non-
disease genes [3, 79]. This strategy selects 99 genes that surround a disease gene on the chromosome as
non-disease genes. During the prediction, each known disease gene and its 99 closest genes are regarded
as unknown. Since similar genes tend to cluster in chromosomal neighborhoods, if an algorithm is more
accurate in identifying disease genes from its neighbor genes, its performance should be better than the
competing algorithms.
2.3.2 PPI network
PPI networks are the most widely used data in all three types of algorithms. Usually, proteins are mapped to
their corresponding genes to form a gene interaction network. In this section, we will use genes and proteins
interchangeably. Right now, many databases are available for researchers to download PPI networks. Table
2.2 summarizes several databases and the date of their latest updates. The first four databases (BioGRID,
HPRD, MINT, and DIP) collect PPIs from published literature while the rest ten databases also collect
PPIs from other databases. Among these databases, INstruct curates the interactions and constructs a 3D
PPI network.
From Table 2.2, we can find that more than half of the databases have not been updated for at least one
4[78] is Chapter 3 from this thesis
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Table 2.2: Some commonly used databases of PPI networks
Name URL Ref. Latest Update
BioGRID https://thebiogrid.org [88] 12/25/2018
HPRD http://www.hprd.org [89] 04/13/2010
MINT https://mint.bio.uniroma2.it [90] 09/01/2013
DIP https://dip.doe-mbi.ucla.edu/dip/Main.cgi [91] 02/05/2017
INstruct http://instruct.yulab.org [92] 04/15/2013
STRING https://string-db.org [93] 01/19/2019
InWeb IM http://www.intomics.com/inbio/map [94] 09/12/2016
IntAct https://www.ebi.ac.uk/intact [95] 12/01/2018
PINA http://omics.bjcancer.org/pina [96] 05/21/2014
HIPPIE http://cbdm-01.zdv.uni-mainz.de/~mschaefer/hippie [97] 07/18/2017
HINT http://hint.yulab.org [98] Version 4
iRefIndex http://irefindex.org/wiki/index.php?title=iRefIndex [99] 01/22/2018
Mentha https://mentha.uniroma2.it [100] 01/28/2019
I2D http://ophid.utoronto.ca/ophidv2.204 [101] 07/10/2015
year. Meanwhile, since protein interaction is tissue-specific and dynamic, PPI networks downloaded from
these databases contain many false positives [4], which significantly affects the accuracy of the prediction,
especially for network-based methods. Many approaches have been proposed to improve the quality of the
downloaded PPI networks. One of them is to filter out PPIs with low confidence scores. A few databases,
such as STRING and InWeb IM, offer confidence scores which represent the reliability of the PPI. PPIs with
low confidence scores are usually collected from animal experiment or computational prediction, which can
be removed if users need a high-quality network.
2.3.3 Gene expression
Gene expression profiles are the second most popular data for disease gene prediction. Before the widespread
use of next-generation sequencing technologies, gene expression data measured by microarray or RNA-seq
are the most accessible data to enhance the prediction of disease genes. Although gene expression cannot
directly provide association information, the expression pattern of genes in different groups of samples helps
us identify disease genes.
Gene expression data can be used to extract features, weight the PPI networks, and build tissue-specific
networks. We can also use them to build independent networks, such as co-expression networks [48], reg-
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ulatory networks and differential co-expression networks [78] 5. The datasets of gene expression can be
obtained from many platforms, such as the Gene Expression Omnibus (GEO) [102, 103] and Genomic Data
Commons (GDC) Data Portal (previously known as TCGA) [104]. Similar to PPI networks, gene expression
data suffer from quality issues. No matter how the expression levels are measured (microarray or RNA-seq),
preprocessing should be performed to remove low-quality samples and non-expressed genes. Moreover, the
data have to be normalized before cross sample analysis, especially for RNA-seq data, which are usually not
normalized. Many algorithms have been proposed to normalize the raw RNA-seq count data, and details of
their comparison can be found in [105].
Among all the applications of gene expression, co-expression analysis is the most frequently used one.
Co-expression patterns, especially differential co-expression, reveal disease-associated properties, and many
algorithms have used them to predict disease genes [106]. However, both co-expression and differential co-
expression characterize only a part of the disease gene-related information. Neither of them can solve the
problem alone, and gene expression data should be integrated with other types of data when designing a
computational method.
2.3.4 Mutation data
Unlike other types of data which mainly provide functional similarity information, mutation data contain the
association information between diseases and mutations, which has accelerated the identification of disease
genes. Currently, mutation data are obtained from sequencing studies, such as GWAS, Whole Exome
Sequencing (WXS) and Target Sequencing (TS).
In typical GWAS, patients and normal controls are genotyped to identify disease-associated single nu-
cleotide polymorphisms (SNPs). For each SNP, a P -value calculated from statistical tests is used to represent
its likelihood of being disease-associated. These SNPs can be further mapped to their corresponding genes
to generate a group of candidate disease genes. Generally, an SNP is mapped to a gene if it is located within
the gene sequence or 20 kb upstream or downstream. If multiple SNPs are mapped to the same gene, the
most significant SNP (the one with the smallest P -value) would be chosen. Post-GWAS algorithms then
combine these candidate disease genes and their mapped P -values with other types of data, such as PPI
network, to select a subset of genes as disease genes.
Another type of data that can be obtained from GWAS are the expression quantitative trait loci (eQTL).
Mutations in these loci can modulate the expression of genes, which might lead to diseases. Based on the
distance between the loci and the genes, eQTL can be divided to cis (close to a gene) and trans (distal to
a gene or on different chromosomes). Studies have shown that trans eQTL are more important than cis
eQTL for their influence on gene expression [107, 108]. Since eQTL can provide additional disease-related
information, algorithms have combined SNPs and eQTL to improve the accuracy of disease gene prediction
5[78] is Chapter 3 from this thesis
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Table 2.3: Some commonly used databases of Pathways
Name URL Ref. Latest Update
KEGG https://www.genome.jp/kegg [119, 120, 121] 01/01/2019
Reactome https://reactome.org [122] 12/13/2018
WikiPathways https://www.wikipathways.org [123] 01/01/2019
Pathway Commons https://www.pathwaycommons.org [124] 01/28/2019
[109, 110].
Currently, several databases collecting GWAS data are available, such as GWAS catalog [111] and dbSNP
[112]. The most popular eQTL database is GTEx Portal. Researchers can also obtain eQTL data of specific
tissues from references [113, 114].
In WXS and TS studies, various types of somatic mutations [single nucleotide variants (SNVs), insertions
or deletions (indels), etc.] are identified, and computational algorithms can predict disease genes by analyzing
their frequency or functional impact. However, unlike GWAS which has been conducted for more than ten
years. WXS relies on the next generation sequencing technologies, and mutation data measured from these
studies are not always available for all kinds of diseases. Thus, somatic mutation data are not further
discussed in this review. Studies about analyzing somatic mutation data can be found in [13].
2.3.5 Pathway
It is well known that disease genes of the same or similar diseases may exist in the same biological module,
such as protein complexes [115], and pathways [116]. Therefore, pathways are also valuable for disease gene
prediction. Table 2.3 lists a few pathway databases that are commonly used in computational algorithms.
In earlier stages, some computational algorithms regarded unknown genes in the same pathway with the
known disease genes as candidates and identified real disease genes from them [15]. Later on, Chen et al.
extracted features from a pathway co-exist network in which two genes were connected if they belonged to the
same pathway [117, 118]. Currently, pathways are more commonly used to validate the do novo prediction
of the algorithms. The corresponding methods are discussed in Section 2.4.3.
2.3.6 Other types of data
Apart from the widely used data discussed in the previous sections, many other types of data are also useful
in predicting disease genes. One of them is ontology data, which includes gene ontology [125, 126] and
phenotype ontology [127, 128]. Ontology terms can be described by directed acyclic graphs (DAG) where
nodes represent terms while edges represent semantic relations. The major application of gene (phenotype)
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ontology in disease gene prediction is to calculate the similarities among genes (diseases) [129, 64] 6. A few
algorithms have been proposed to calculate the semantic similarities based on ontology data [130, 131]. We
can also extract features from gene ontology data and train machine learning models with them [41, 132].
Moreover, databases like MeSH, also contains disease terms in the form of DAG which can be used to
compute disease similarities [133].
Another type of data is subcellular localization, which represents where a protein resides in cells. There
are 11 compartments, and two proteins may not interact with each other if they are not localized in the
same compartment. Databases such as COMPARTMENTS [134] and LOCATE [135] contain experimentally
validated subcellular localization data. Based on our experience, directly using data obtained from these
databases and removing protein interactions if two proteins are not in the same compartments might not
improve the prediction accuracy, since subcellular localization information is still being identified. A better
choice is to weight the PPI networks with the currently available localization data using the strategy proposed
in [136, 79].
Finally, protein sequence and domain information are related to the protein functions, which is valuable
for disease gene prediction. However, due to their complexity, only a few algorithms have used them in the
prediction [137, 41].
2.3.7 Data integration
Each type of data discussed in previous sections characterizes its unique biological properties. To improve
the prediction accuracy, it is necessary to properly integrate different types of data so that their shortcomings
are compensated. Currently, network-based strategies are most commonly used in integrating multiple types
of data.
Network-based
A. Single network-based
Single network-based strategies focus on weighting the PPI network with additional information. Generally,
pair-wise measurements, such as correlation coefficients, subcellular localization and gene similarities, can
be used to weight the edges of the network, while single gene-related information, such as average expression
level, P -values mapped from GWAS data, can be used to weight the nodes of the network.
Additionally, PPI networks can be curated to improve its accuracy. A typical example is to construct
tissue-specific networks based on gene expression data. The key idea is to remove a protein interaction if one
of the two interacting genes is not expressed in the corresponding tissue. However, it is difficult to determine
whether a gene is expressed or not. Earlier method regarded a gene as expressed if its expression level was
higher than a threshold [138]. Later on, Ganegoda et al. calculated the PCC of all interacting genes and
6[64] is Chapter 5 from this thesis
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removed an edge if its corresponding PCC was lower than a threshold [39]. Ni et al. also used PCC of the
gene expression to construct a tissue-specific PPI network, except that they constructed the network using
the k-nearest-neighbor strategy where each gene in the PPI network was connected with its top k “nearest”
genes based on the PCC [139].
Although co-expression-based methods are better than those with a unified threshold, neither of them
are optimal. To make the obtained network more informative for disease gene prediction, Luo et al. proposed
an algorithm to construct sample-specific networks [43] 7. Specifically, a unique network was generated for
each disease (case) sample. A gene i was considered expressed in a case sample if its expression level was
higher than λ ·mean(cntl[i]), which was the mean expression levels of i in the control samples. λ was then
chosen by the grid search based on the performance of the algorithm. Although this strategy might remove
several true positive PPIs from the network, the remaining PPIs were closely related to the disease, which
should improve the prediction of disease genes. Results of the experiments showed that prediction based on
this strategy was more accurate than some previous ones, such as the subcellular localization-based method
[79].
Finally, researchers can also build functional interaction (FI) networks to replace the PPI network. In
an FI network, genes are connected if their functional similarities are above a defined threshold. Thus, the
connected genes do not need to physically interact. The functional similarities can be calculated from protein
interaction, gene expression, pathway and many other types of data [140].
B. Multiple network-based
Multiple network-based strategies construct a few biomolecular networks and combine them together. For
instance, a heterogeneous network is constructed by disease similarity network, PPI network and bipartite
network which represents disease-gene associations. Since disease similarity is used in a heterogeneous
network, evidence for estimating disease similarities can all be used to construct heterogeneous networks.
Meanwhile, heterogeneous networks can also be used to integrate multi-omics data. For instance, Lei et
al. constructed a triple heterogeneous network where lncRNA–lncRNA similarity network, gene–lncRNA
associations and lncRNA–disease association were fused into the network [30].
Feature-based
Feature-based strategies are used in machine learning-based methods. Raw features extracted from each
type of data can be fused by deep learning models such as DBN and graph CNN. Details of these models
are discussed in Section 2.2.2. Although the learning process is in a black box, the fused representations
improved the prediction accuracy according to existing studies.
7[43] is Chapter 4 from this thesis
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2.4 Evaluation methods
Many strategies have been used to evaluate the performance of computational algorithms; however, no gold
standard has been proposed. In this section, we present a two-step approach for researchers to evaluate their
own algorithms. The two steps consist of the minimum required strategies that should be used for evaluation.
In the meantime, we also introduce several other evaluation methods, and researchers are encouraged to use
them to further evaluate their algorithms.
2.4.1 Step 1: metrics
The first step to evaluate an algorithm is to compare it with other state-of-the-art methods using different
metrics. Since generating a probability (or a score) for each gene, rather than a binary label, is more helpful
for scientists to select potential disease genes, metrics such as the area under receiver operating characteristic
(ROC) curve (AUC) and the area under Precision–Recall (PR) curve (AUPR) are recommended to compare
different algorithms. ROC curve plots the true positive rate (TPR) versus the false positive rate (FPR) at
different thresholds, and PR curve plots precision against recall (also known as TPR) at different thresholds.
A larger area under the curve represents better overall performance. Due to the small size of input data,
computational methods usually use cross-validation to obtain the prediction results. 5-fold cross-validation
and leave-one-out are two commonly used approaches.
To calculate precision, recall and FPR, known disease genes are regarded as positives, while non-disease
genes are regarded as negatives. Given a threshold, these metrics can be calculated by
precision =
# of TPs
# of TPs + # of FPs
recall =
# of TPs
# of TPs + # of FNs
FPR =
# of FPs
# of FPs + # of TNs
(2.6)
where a TP (true positive) is a known disease gene predicted as positive; a FP (false positive) is a non-disease
gene predicted as positive; a TN (true negative) is a non-disease gene predicted as negative; a FN (false
negative) is a disease gene predicted as negative.
Usually, AUC is suitable for balanced datasets while AUPR is more useful for imbalanced datasets [11].
Considering that algorithms with high recall rate are more valuable (correctly predict true disease genes is
more useful), another metric known as “recall rates at different thresholds” can be used in concert with AUC
or AUPR to demonstrate the superiority of the algorithm. An algorithm with higher recall rate within the
top k (typically, k = 100) genes is superior to its competing algorithms.
Other than AUC and AUPR, researchers can also rank all the genes based on their probabilities and
calculate the “cumulative distribution function (CDF) of the rank”. CDF characterizes the number of
disease genes that are ranked in the top k genes of the predicted list as a function of k. Similar to “recall
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rates at different thresholds”, CDF of the rank also measures the algorithm’s ability in predicting true disease
genes with different thresholds.
In summary, researchers should choose one of the three metrics (AUC, AUPR, and CDF) to evaluate
their methods.
2.4.2 Step 2: de novo study
As discussed in Section 2.3.1, a high accuracy might be the results of well selected non-disease genes. To
further demonstrate the performance of the algorithm, a de novo study should be conducted as the second
step to evaluate the proposed algorithm. Specifically, researchers should use their algorithms and search the
predicted disease genes against those known from existing literature. Usually, disease genes are not collected
into databases unless their associations have been proved by multiple studies. Thus, it is possible that a
gene has been identified as a disease gene by a few studies, but still has not been collected by the benchmark
dataset. If most of the genes in the top k (usually k = 10) predictions have been experimentally identified
as disease-associated, the algorithm would be a valuable one.
2.4.3 Other evaluation methods
The two-step approach provides the typically required evaluation methods to demonstrate the performance
of an algorithm. In many studies, researchers tend to use additional methods to further evaluate the per-
formance of their algorithms. For instance, pathway enrichment analysis (PWEA) identifies statistically
significant gene sets which represent functions, mechanisms, processes, etc. Given a set of predicted disease
genes, PWEA uses statistical tests to verify if a pathway is over-represented among input gene sets com-
pared to the whole genome [141]. Results of the analysis are a list of pathways, each of which with a P -value
represents its significance. The more significantly enriched disease-related pathways are found in the results,
the better the algorithm performs. Another method is to use databases, such as DisGeNET, to research
PubMed IDs of newly published articles that report the predicted disease-gene associations.
2.5 Perspectives and conclusions
In this review, we have discussed several types of computational methods for predicting disease genes.
Based on their characteristics, we roughly divide them into three groups: network-based methods, machine
learning-based methods, and other methods. For each type of method, we discussed those that are valu-
able for developing new algorithms. Note that a thorough comparison is not provided in this review since
different methods use different types of data, and a method with lower accuracy could still be valuable for
developing new algorithms. For instance, many NMF-based methods outperformed IMC in their evaluations.
However, with new disease and gene features, a modified IMC still performed much better than most NMF-
based methods [142]. Therefore, when developing new algorithms, researchers should incorporate different
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strategies properly and leverage the advantages of various types of methods. Despite the good performance,
existing algorithms might be improved in several ways to allow more accurate prediction.
For network-based methods, the state-of-the-art algorithms are those that use a random walk to predict
disease genes. The contribution of a path to the prediction score decreases exponentially with its length,
which might not be the best option for prediction. If we set different weights for different path lengths, the
random walk might be more controllable which might generate better predictions. Another issue is that
many algorithms are biased towards hub genes. Using P -value instead of original prediction scores could
solve this problem [129, 143]. Moreover, the performance of network-based methods depends highly on the
quality of the network. Although using multiple networks or heterogeneous networks can improve prediction
accuracy, most approaches still focus on genomics data. Researchers should develop more architectures that
can use multi-omics data to enhance the prediction.
For machine learning-based methods, the selection of negative data is a critical issue. A good non-
disease gene selection strategy might find a group of highly possible negative data, resulted in high AUC and
AUPR scores. However, the accuracy of the model in predicting new disease genes may not be satisfactory,
since passenger genes are not like those selected non-disease genes, which can be easily separated from
known disease genes. The two-step strategy which filters out those highly possible non-disease genes in the
first step might help researchers design a good model [117, 118]. Furthermore, a bootstrap strategy which
allows the model to be trained with multiple types of negative data should also improve the discriminative
power of the algorithms. In addition to negative data, machine learning-based algorithms might also be
biased toward hub genes. This issue is mainly raised by the features extracted from biomolecular networks.
Combining traditional features with novel representations, such as mutation-based features [144, 145] or
graph embeddings [146] should solve this issue. Last but not least, more and more studies have used deep
learning to solve biomedical issues [147]. Deep learning models can directly learn features from raw sequence
data and expression data, which might provide more valuable representations than traditional hand-craft
features. Meanwhile, newly developed models such as graph CNN also provide a new way for data integration,
and combining graph CNN with heterogeneous networks would allow us to learn representations from multi-
omics data.
Another problem lies in the need for a high-quality disease-gene association database for complex diseases.
Although many databases have been released, researchers tend to have divergence in determining whether
a gene is disease-associated or not. Association data downloaded from different databases vary a lot for
some complex diseases. Thus, an advanced database for complex diseases would be extremely valuable for
computational algorithms.
Finally, computational algorithms are developed to assist the experimental identification of disease genes;
however, most of them have not been used in wet-lab studies. The main reason is that most algorithms have
not been implemented as user-friendly software tools. Even if the authors have provided the source codes,
users still need to preprocess their data so that the algorithms can be performed. This issue is extremely
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critical when the algorithms require multiple types of data. Thus, implementing these algorithms to a
web tool or user-friendly software package would significantly improve their practicability in disease gene
discovery. For instance, Endeavour provided a web tool for users to predict disease genes using multiple
types of data [70]. Studies conducted for the identification of Autism-associated genes [148] and Parkinson’s
disease-associated genes [149] have used Endeavour to prioritize candidate genes. Similarly, WGCNA has also
been used to analyze expression data and identify disease-associated modules [50, 51]. Note that algorithms
that have not been developed to an online tool still contribute a lot to the prediction of disease genes. These
algorithms provide insights on how to analyze biological data and predict disease genes, which might be used
in other tools and areas.
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As discussed in Chapter 1, disease-gene prediction is a positive-unlabeled learning problem, where only
positive instances (disease genes) are available in benchmark datasets. To train and evaluate the models,
non-disease genes have to be selected as negative instances. Most algorithms randomly select a group of
unknown genes as non-disease genes, some of which might be real disease genes. A strategy should be
proposed to select a set of highly possible non-disease genes.
In this chapter, a shortest path-based strategy is proposed to combine OMIM data and clinical gene
expression data and select reliable non-disease genes. Applying these non-disease genes with energy-based
model shows that these negative instances can significantly improve the prediction accuracy. This chapter
fulfills Objective 2 of this thesis.
Abstract
Disease gene prediction is a challenging task that has a variety of applications such as early diagnosis and
drug development. The existing machine learning methods suffer from the imbalanced sample issue because
the number of known disease genes (positive samples) is much less than that of unknown genes which are
typically considered to be negative samples. In addition, most methods have not utilized clinical data from
patients with a specific disease to predict disease genes. In this study, we propose a disease gene prediction
algorithm (called dgSeq) by combining protein-protein interaction (PPI) network, clinical RNA-Seq data,
and Online Mendelian Inheritance in Man (OMIN) data. Our dgSeq constructs differential networks based
on rewiring information calculated from clinical RNA-Seq data. To select balanced sets of non-disease genes
(negative samples), a disease-gene network is also constructed from OMIM data. After features are extracted
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from the PPI networks and differential networks, the logistic regression classifiers are trained. Our dgSeq
obtains AUC values of 0.88, 0.83 and 0.80 for identifying breast cancer genes, thyroid cancer genes and
Alzheimer’s disease genes, respectively, which indicates its superiority to other three competing methods.
Both gene set enrichment analysis and predicted results demonstrate that dgSeq can effectively predict new
disease genes.
3.1 Introduction
Complex diseases are usually caused by the malfunction of a group of genes, known as disease-associated
genes or disease genes. Identifying these genes is critical for understanding the mechanisms of diseases.
Traditional methods such as GWAS and linkage analysis usually generate hundreds of candidate disease
genes, making the further validation time-consuming and expensive [11]. As a result, many researchers have
developed efficient computational methods to predict and prioritize candidate disease genes to reduce the
number of candidates while helping scientists optimize the in-depth wet lab validation.
Based on whether the algorithms require known disease-gene associations as input, existing algorithms
can be divided into two categories: undifferentiated and differentiated [11]. Undifferentiated algorithms
treat all the genes in the genome equally, and provide overall probabilities for all the genes involved in a
disorder. For instance, dmGWAS [150] and EW dmGWAS [58] first searched dense modules from a PPI
network weighted by GWAS and gene expression data. Then, genes in the top 1% of the ranked modules
were regarded as disease genes. MetaRankder 2.0 prioritized candidate genes by integrating five kinds of
heterogeneous data [151]. Text mining algorithms such as MeSHOP [152] and Genie [153] searched candidates
from biomedical literature and generated a list of ranked genes for a given specific disease. Those methods
are useful especially for disorders that have no known disease genes.
Differentiated algorithms analyze the known disease genes along with other biological data, and provide
more valuable information than undifferentiated algorithms. Many machine-learning-based and statistics-
based algorithms are differentiated. An example is the popular tool Endeavor, which prioritized candidate
genes according to the relationships between user submitted training genes and candidate genes in various
kinds of biological data. Another example is the network energy-based algorithms proposed by Chen et
al. [48, 117, 118], where genes are classified as being disease-associated or not according to the posterior
probabilities calculated by a formula derived from the Boltzmann distribution and their defined network
energy function.
Differentiated algorithms, especially machine learning-based algorithms, have gained success in the pre-
diction of various kinds of disease genes. However, since the number of known disease genes (positive samples)
is far less than that of unknown genes (negative samples), most machine learning-based algorithms have to
face an imbalanced classification problem. Moreover, no databases contain non-disease genes for a specific
disease. Thus, training an accurate machine learning model for predicting disease genes is usually difficult.
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To solve this imbalanced classification issue, one possible solution is to divide the individual diseases into
disease classes. Since the number of genes in each class is much more than that of a specific disease, training
a model with disease classes is possible. Algorithms such as the RWR of Ko¨her et al. [18] and the MRF
method of Chen et al. [47] used this strategy. Another approach is to narrow down the non-disease genes
space. For instance, in their “two step” method [117], Chen et al. first removed the genes with low relevance
to the disease under consideration, then predicted disease genes from the remaining genes. This strategy
successfully predicted cancer-related genes; however, negative samples in the training set were still five times
higher than positive samples. As well, the method required individual diseases to be laboriously classified
into disease classes. Although Goh et al. classified disease genes into 22 classes in [154], their dataset was
out of date. Databases such as Online Mendelian Inheritance in Man (OMIN) [155] are updated daily and
require time and expertise to be classified.
In this study, we propose a strategy to reduce the number of non-disease genes. Unlike existing meth-
ods, our strategy selects non-disease genes for a specific disease rather than a disease class. The obtained
non-disease genes are directly selected from the latest OMIM dataset. No classification is needed in the
process, thus improving the accuracy and efficiency of the algorithm. Additionally, since the number of non-
disease genes in the training set is similar to the number of disease genes, our model avoids the imbalanced
classification problem.
In addition to non-disease gene selection strategy, we integrate PPI networks and RNA-Seq Data to
improve the prediction accuracy. Previous research has shown that the integration of PPI networks and gene
expression data is valuable for predicting essential proteins and protein function [156, 157]. In this work, we
integrate these two types of data by extending our previous study on ‘guilt by rewiring’ [158]. A network
is considered to be rewired if its edges (wires) are changed during a specific process. This phenomenon
is observed in many biomolecular networks, such as regulatory networks, protein-protein interaction (PPI)
networks and co-expression networks. Previous studies have shown that network rewiring is an important
implication for analyzing biological data. For instance, Hu et al. showed that besides differential expression,
rewiring information was very useful for analyzing gene expression data [159]. In our study, the rewiring
of co-expression network from control to case subjects is used to predict disease genes. In [160], Hou et al.
demonstrated that co-expression between disease genes were more frequently rewired than a random pair
of genes. The major reason behind this phenomenon is that disease genes are usually extensively expressed
in case subjects compared to control subjects (differential expression), while non-diseases may maintain a
stable expression level in different conditions. This difference raises the variance of the correlations between
genes, which is reflected on the co-expression network.
In [158], the rewiring information calculated from gene expression under different conditions (case and
control) was employed to weight the PPI network, and predicted disease genes through a logistic regression
model trained on the features extracted from the weighted PPI network. This strategy is usually useful,
except for non-disease genes with large degrees. Although the average weights (rewiring information) around
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these genes are less than real disease genes, they may have similar features as disease genes because of
their high degrees. To solve this problem, in this study, instead of weighting the PPI network with gene
expression data, we used the rewiring information computed from expression data to build an independent
scale-free differential network. This differential network, combined with the PPI network, is employed to
extract features for predicting disease genes. The new features extracted from two networks can reveal the
topological structure of PPI and the rewiring information of all genes at the same time, which can solve the
problems in the previous model. The challenges of the new model is to build a valuable differential network,
which is discussed in Section 3.2.2. It is noting that the expression data in [158] was measured by microarray,
which has been replaced by RNA-Seq by many databases because of its limitations. Thus, in this study, the
rewiring information is calculated from clinical RNA-Seq data instead. Experiments performed on Breast
Cancer (BC), Thyroid Cancer (TC) and Alzheimer’s disease (AD) reveal that our new algorithm is superior to
existing methods. An implementation of dgSeq is available at: https://github.com/luoping1004/dgSeq.
The rest of the paper is organized as follows. Section 3.2 describes the methods and materials used in
the study. Section 3.3 analyzes the experimental results of the algorithm and compares dgSeq with three
other competing algorithms. Section 3.4 draws some conclusions.
3.2 Methods and materials
The work flow of the algorithm is depicted in Fig. 3.1. First, the RNA-Seq data from case subjects (a)
and control subjects (b) are used to build a differential network by the strategy proposed in Section 3.2.2
(c). Then, a disease-gene network (d) is constructed with OMIM data, and labels of all the genes (e) are
determined by (c), (d) and benchmark disease genes. These labels are used to label the PPI network (f) and
differential network (c). After that, features of the known disease genes and non-disease genes are extracted
from (c) and (f). A logistic regression model (h) is trained by the extracted feature matrix (g) and its
corresponding labels (e). Finally, the probability of a gene being labeled as 1 (disease gene) (i) is calculated
in each round of the cross validation. Details of the algorithm are discussed in the following subsections
3.2.1–3.2.4. Subsections 3.2.5 and 3.2.6 explain the validation methods and data sources, respectively.
3.2.1 General model
Identifying disease genes from a biomolecular network can be formulated as a network labeling problem in
which disease genes are labeled as 1 while non-disease genes are labeled as 0. Let g1, g2, . . . , gh represent
all the h genes in the network. A set of binary labels x = (x1, x2, . . . , xh) of these h genes is known as a
configuration of the biomolecular network, and the set of all possible configurations X is a random field.
The probability distribution of the configuration x of a random field X can be calculated by Boltzmann
distribution [45]
P (x) =
1
Y
· exp(−κH(x)) (3.1)
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Figure 3.1: The work flow of dgSeq. (a)–(b). Clinical RNA-Seq data of the case and control subjects;
(c). Differential network constructed by (a) and (b); (d) disease-gene network constructed by OMIM
data; (e). Labels of all the genes determined by (c), (d) and benchmark disease genes; (f). PPI
network; (g). Feature matrix extracted from (c) and (f); (h). Logistic regression model trained with
(e) and (g); (i). The calculated probabilities of all the genes being labeled as 1 (disease gene).
where H(x) is the Hamiltonian (energy) of the configuration x, κ is a positive constant parameter, and Y is
called the partition function and defined as Y =
∑
x∈X exp(κH(x)).
Let x[−i] be the binary labels of all nodes except for node i in a network. Then, knowing the labels
(disease or non-disease) of other genes (that is, x[−i]), the probability that gene i is a disease gene is a
conditional probability P (xi = 1|x[−i]). By Bayes’ rule we have
P (xi = 1|x[−i]) =
P (xi = 1, x[−i])
P (xi = 1, x[−i]) + P (xi = 0, x[−i])
(3.2)
In (3.2), (xi = 1, x[−i]) is the configuration that gene i is a disease gene while (xi = 0, x[−i]) is the con-
figuration that gene i is a non-disease gene. The probability of both configurations can be calculated by
(3.1).
By adopting the Ising model to calculate the Hamiltonian in [46, 47, 48], the probability P (xi = 1|x[−i])
in (3.2) can be parameterized as follows
P (xi = 1|x[−i], µ˜) = e
α+βMi0+γMi1
eα+βMi0+γMi1 + 1
(3.3)
where µ˜ = (α, β, γ) are model parameters. Mi0 and Mi1 are the numbers of neighbors of node i with label
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0 and 1, respectively. Furthermore, if Z networks are available for determining disease genes, (3.3) can be
generalized as follows [46]
P (xi = 1|x[−i], µ) = exp(V (i))
exp(V (i)) + 1
(3.4)
where
V (i) = α+
Z∑
z=1
[βz ·Mzi0 + γz ·Mzi1],
µ = (α, βz, γz) (z = 1, . . . , Z) are model parameters. Mzi0 and M
z
i1 are the number of neighbors of node i
with labeled 0 and 1 in the z-th network, respectively. Clearly, (3.4) follows a logistic model
P (xi = 1|x[−i], µ) = exp(µ
Tϕi)
exp(µTϕi) + 1
(3.5)
where
ϕi = (1,M
1
i0,M
1
i1, . . . ,M
z
i0,M
z
i1)
T (3.6)
µ = (α, β1, γ1, . . . , βz, γz)T .
We can also have
P (xi = 0|x[−i], µ) = 1− P (xi = 1|x[−i], µ)
=
1
exp(µTϕi) + 1
(3.7)
which computes the probability of a gene being labeled as 0.
Given a known configuration, the parameters in µ can be estimated by the following likelihood function
µˆ = arg max
µ
(
h∏
i=1
P (xi|x[−i], µ)) (3.8)
However, since the number of disease genes is far less than that of unknown genes, the parameter estimated
by (3.8) is inaccurate because of the sample imbalanced problem. To address this problem, we employ the
under sampling strategy which uses (3.9) to replace (3.8) in this study.
µˆ = arg max
µ
(
2m∏
i=1
P (xi|x[−i], µ)) (3.9)
For the disease d under consideration, m is the number of known disease genes associated with d. Sndg
contains a set of non-disease genes. We perform the under sampling to randomly select m non-disease genes
from Sndg, and (3.9) estimates µ based on the features of the m disease genes and m non-disease genes.
The under sampling is performed 100 times and each time computes a µ which is then used to compute the
probabilities of unknown genes being labeled as 1. Finally, for each unknown gene, its average probability of
being labeled as 1 in the 100 runs is regarded as its probability of being disease-associated. The algorithm
for defining non-disease genes with d is discussed in Subsection 3.2.3.
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Maximizing the likelihood function in (3.9) is equivalent to maximizing the log likelihood function in
(3.10) as follows
µˆ = arg max
µ
L(µ) (3.10)
where
L(µ) =
2m∑
i=1
ln(P (xi|x[−i], µ)) (3.11)
Substituting (3.5) and (3.7) into (3.11) yields
L(µ) =
2m∑
i=1
{xiµTϕi − ln[1 + exp(µTϕi)]} (3.12)
Since (3.12) is a concave function of µ [161], the optimization problem (3.10) can be solved by Python’s
library SciPy using the optimization function minimize() through searching the minimum solution of the
convex function −L(µ) [162].
3.2.2 Differential network construction
Not only are the expressions of disease genes in case subjects are significantly different from those in control
subjects, but also their correlations in case subjects should also be significantly different from those in control
subjects (rewiring). Actually, it is believed that a pair of disease genes are more frequently rewired than
a random pair of genes in the genome. To take the rewiring information into account, in this study the
differential networks are constructed with clinical RNA-Seq data.
Given two genes gi and gj with their corresponding v-dimensional expression values (gi1, gi2, . . . , giv) and
(gj1, gj2, . . . , gjv), respectively, their Pearson correlation coefficient (PCC) can be calculated as follows
r(gi, gj) =
∑v
q=1(giq − g¯i)(gjq − g¯j)√∑v
q=1(giq − g¯i)2
√∑v
q=1(gjq − g¯j)2
(3.13)
where g¯i and g¯j are the mean of the expression values of gi and gj , respectively.
For a pair of genes gi and gj , let r
case
ij denotes the PCC between the expression of genes gi and gj in case
subjects, and rcntlij denotes their PCC in control subjects. Instead of Fisher’s test of difference used in our
previous study [158], we directly compute an absolute value
pij = |rcaseij − rcntlij | (3.14)
for all pairs of genes i and j (i, j ∈ [1, h], i 6= j), and obtain a correlation difference matrix
P =

p11 p12 . . . p1h
p21 p22 . . . p2h
...
...
. . .
...
ph1 ph2 . . . phh

which contains the rewiring information between the case and control subjects.
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Figure 3.2: Scatter plot of the log-log degree distribution of Gdif for BC .
Although matrix P could be used as an adjacency matrix to construct a differential network, this net-
work would contain too much noise since the process of producing clinical RNA-Seq data has various noisy
resources. To filter out the noisy edges which typically correspond to a small value in matrix P , we use the
k nearest neighbors (K-NN) algorithm [163] to determine whether an edge should be kept. Specifically, for
gene i, the largest k entries in the i-th row of the matrix P are kept while others are set to be zeros. Let pij
represent one of the k kept entries in row i. Then an edge is added between i and j for each of the k entries.
Finally, a differential network Gdif is built by adding edges for all the largest k entries in every row of the
matrix P .
For different values of k, the degree distribution of the constructed differential network is different. Then,
it is nontrivial to choose a reasonable k for constructing a meaningful differential network. Since many
biological networks are scale-free, such as the PPI network used in our study, it is believed that a scale-free
differential network would be more reasonable. We use different values of k to construct the networks, and
find that the differential networks are scale-free for all values of k from 3 to 9. However, the large value of k
may include more noisy edges while the small value may exclude more informative edges. In this study, we
use k = 5 in the experiments. More details about this threshold is discussed in the Results. Fig. 3.2 shows
the scatter plot of the log–log degree distribution for Gdif with k = 5 constructed based on BC’s clinical
RNA-Seq data. Apparently, Gdif is scale-free. The other differential network for TC is similar to Fig. 3.2.
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Figure 3.3: Sample disease gene network
3.2.3 Non-disease genes
Although no databases contain disease specific non-disease genes, we adopt a strategy to determine non-
disease genes. The strategy includes three steps. First, we build a disease-gene network (DGN) from OMIM
data and select a group of genes from DGN as potential non-disease genes. Second, another group of non-
disease genes are collected from the differential network Gdif . Third, two groups of candidate non-disease
genes are combined to form the final set of non-disease genes.
Select non-disease genes from DGN
A disease-gene network is built to select the initial group of non-disease genes. In this network, each node
represents either a disease or a disease-associated gene. Every disease node is connected with its associated
gene nodes, and two disease nodes are connected if they share at least one same disease-associated genes.
To illustrate, Fig. 3.3 depicts a sub network of DGN with 5 diseases (d1, d2, d3, d4, d5) and 5 disease genes.
d1 and d2, d2 and d3, d3 and d4, d4 and d5 are connected because they share at least one disease-associated
gene.
The length of the shortest path between two diseases in the DGN represents their relationships. Length
of 1 (d1 and d2) indicates two diseases have at least one same disease-associated gene. Length of 2 (d1 and
d3) indicates that there is some other disease to which both two diseases are connected. Length of 3 (d1 and
d4) indicates that the neighbors of two diseases are connected. If two diseases are neighbors, they may have
similar mechanisms. Thus, d1 and d3 may have similar mechanisms because both of them are connected
with d2. d1 and d4 may also have similar mechanisms because d2 and d3 are connected with each other.
Moreover, d1 and d4 are less likely to have similar mechanism compared to d1 and d2. Therefore, the longer
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of the shortest path between two diseases in DGN, the less possible they have similar mechanisms. If two
diseases di and dj have completely different mechanisms, their associated disease genes should have different
properties, which means the disease genes of one disease di can be regarded as the non-disease genes of
another disease dj .
To determine whether the distance between two diseases is enough to show that they have different
mechanisms, we need to set a threshold for the length of the shortest path. If we set the threshold to 4, in
a special situation, g12 would be a non-disease gene of d5 because the length of the shortest path from d1
to d5 is equal to 4. However, g12 is also a disease gene of d2 and the distance between d2 and d5 is only 3,
which means g12 should not be a non-disease gene of d5.
To address this problem, let di denotes the disease under consideration, G(d[−i]) denotes the set of genes
in DGN not associated with it. Instead of computing the length of the shortest path between each disease
and di, we compute the length of the shortest path (η) between each gene gk in G(d[−i]) and di. If η ≥ Γ1,
we consider gk as a potential non-disease gene for di. Γ1 is a predefined threshold, which is set as 5 in
this study. If there is no path between gk and di, we also select gk as a non-disease genes. These selected
candidate non-disease genes form a set S1.
Select non-disease genes from Gdif
After selecting non-disease genes from the DGN, we find out that the same strategy can also be employed
on the differential network.
Since disease genes are more frequently rewired, the value pji calculated by (3.14) corresponding to
disease gene i is more likely to be larger than those values corresponding to non-disease genes in the j-th
row. Therefore, compared with a non-disease gene, pji has more chance to be in the largest k entries of
the j–th row. In another word, a disease gene gi is more likely to be connected with other genes in Gdif
than a non-disease gene. Let G(di) denotes the set of m disease genes associated with di, compared to a
non-disease gene, a potential disease gene gk should be closer to the known disease genes in Gdif . Thus, if
the smallest distance of all the shortest paths between gene gk and the genes in G(di) is larger than or equal
to a predefined threshold Γ2, we consider gk as a non-disease gene. In this study, Γ2 is set as 4, and S2 is
used to denote the set that contains all the non-disease genes selected from Gdif .
Generate non-disease gene set
Once we obtain S1 and S2 from DGN and Gdif , respectively, genes in the union of the two sets (Snon =
S1 ∪ S2) are regarded as non-disease genes, and labeled as 0. These genes, along with the m known disease
genes, are used to train the models (3.5) or (3.7). Genes contained in the intersection of the two sets
(Sndg = S1 ∩ S2) are considered to be non-disease genes with the highest possibilities. We randomly select
m genes from Sndg as the benchmark non-disease genes. These genes along with the m known disease genes
are used in the cross-validation.
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3.2.4 Feature extraction
Considering that we have two networks (PPI and Gdif ) in the study, feature vector (3.6) is specified as
follows
ϕi = (1,M
1
i0,M
1
i1,M
2
i0,M
2
i1)
T (3.15)
where M1i0 and M
1
i1 (M
2
i0 and M
2
i1) represent the numbers of neighbors of gi which are labeled as 0 and 1 in
the PPI network (Gdif ), respectively.
To extract features, we need to assign labels for all the genes in the two networks. As discussed in
the previous sections, disease genes are labeled as 1 while non-disease genes in Snon are labeled as 0. The
remaining genes are treated as unknown. As unknown genes could be disease genes with a small possibility,
in this study 0.01% of them (BC: 119, TC: 126, AD: 100) are randomly labeled as 1 while the others being
labeled as 0. Note that the information of unknown genes with such a labeling is used only for extracting
the features of known disease genes and non-disease genes in Snon, and yet the features of unknown genes
are not extracted and used for estimating the parameters in (3.9).
3.2.5 Validation methods and evaluation criteria
To investigate its performance, we perform the under sampling which randomly selects m non-disease genes
from Sndg 100 times, and run our algorithm 100 times respectively with the set of m disease genes and one
of 100 sets of m non-disease genes. For each pair of benchmark genes, the leave-one-out cross validation
(LOOCV) is employed to validate the algorithm. In each round of the LOOCV, one of the benchmark genes
(the validation gene) is regarded as unknown and labeled randomly as all the other unknown genes. This
strategy allows us to hide the information of the validation gene from the training genes. Then, parameters
in µ (Eq. 3.12) is calculated based on the features of the training genes extracted from the new labels, and
the probability of the validation gene being labeled as 1 is computed by (3.5).
The area under the receiver operating characteristic (ROC) curve (AUC) is employed as one of the
evaluation criteria. The ROC curve plots the true positive rate (TPR) verse the false positive rate (FPR)
at various thresholds. The TPR and FPR are defined as follows:
TPR =
TP
TP + FN
(3.16)
FPR =
FP
TN + FP
(3.17)
where TP , FP , TN , and FN are the numbers of true positive, false positive, true negative, and false
negative, respectively. In this study, a true positive is a disease gene identified as a disease gene, a false
positive is a non-disease gene identified as a disease gene, a true negative is a non-disease gene identified as
a non-disease gene, and a false negative is a disease gene identified as a non-disease gene.
The ROC curve features the TPR on the Y axis, and the FPR on the X axis. This makes the top left
corner of the plot an ideal point, with a FPR of 0 and TPR of 1, and it also means that a method with a
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larger AUC performs better. In this study, we obtain 100 AUC values from 100 runs, the average of which
is used as the AUC of the algorithm.
In terms of AUC, we compare dgSeq with the “two-step” (2Step) and “Rebalancing” (Re-Balanced)
algorithms [117, 118]. These two algorithms outperformed their competing methods in the identification of
cancer-related genes.
To further evaluate our algorithm, we compare dgSeq with Endeavor through gene set enrichment analysis
(GSEA). In a previous study that compared eight public available web-based tools, Endeavor was one of the
two best algorithms when all performance measures were considered [164]. In this study, we first use the
latest version of Endeavor to rank all the unknown genes. Then, for dgSeq, we also rank all the unknown
genes according to their probabilities of being labeled as 1. In each round of the 100 runs, we compute the
probability of each unknown gene being labeled as 1 by (3.5). The corresponding parameter vector µT is
calculated by (3.12) with the features of the 2m benchmark genes in each round. Finally, for each unknown
gene gi, we obtain 100 probabilities, the average of which is regarded as the probability of gene gi being
labeled as 1. The top 100 genes in the two lists are then analyzed and compared in terms of GSEA using
WebGestalt [165, 166, 167].
Finally, deSeq is also evaluated on predicting disease genes associated with Alzheimer’s disease.
3.2.6 Data sources
The BC-associated and TC-associated genes are collected from the Cancer Gene Census category (CGC,
http://cancer.sanger.ac.uk/census#) [87]. 35 BC-associated and 34 TC-associated genes are chosen as the
benchmark disease genes. The AD-associated genes are collected from MalaCards: The human disease
database (http://www.malacards.org/), which contains 182 ranked genes for AD. We select the top 50 as
AD-associated genes. Among these 50 genes, 43 of them appear in the PPI network, and are used as the
benchmark.
The cancer case and control gene expression data are downloaded from the Genomic Data Commons
(GDC) [104]. GDC measures the data by RNA-Seq technique, and provides three types of values: Fragments
Per Kilobase of transcript per Million mapped reads (FPKM), Upper Quartile normalized FPKM (UQ-
FPKM) and the raw mapping count. To facilitate cross-sample comparison, we use the UQ-FPKM values in
the study. In total, the data sets contain 1222 case subjects and 113 control subjects for BC, and 502 case
subjects and 58 controls subjects for TC. The AD RNA-Seq data are downloaded from Gene Expression
Omnibus (GSE53697) [168], which contains the raw mapping count files of 9 case subjects and 8 control
subjects. We normalize the data with DESeq2 [169], because DESeq2 was proved to be one of the best
algorithms for RNA-Seq data normalization [105]. During the preprocessing, genes not in the PPI network
or not expressed (expression values are 0) are removed from the data sets.
The PPI network is obtained from the InWeb InBioMap database (version 2016 09 12) [170], which
consists of 17,653 nodes and 625,641 interactions aggregated from eight source databases. We map proteins
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Figure 3.4: Sensitivity analysis of threshold k
in the network to their corresponding genes, and remove those genes that have no expression data from the
network. To simplify the network, proteins correspond to multiple genes are also removed from the PPI
network. As a result, the final PPI networks contain 16,945 nodes and 589,234 edges for BC, 16,837 nodes
and 587,537 edges for TC, 15056 nodes and 520,211 edges for AD.
The disease-gene association data used to build DGN are obtained from the OMIM database (Feb 17,
2017) [155]. The original data set consists of 4450 diseases and 3402 disease genes when we only consider
the diseases with known molecular basis. Then, the disease genes not in the PPI network are removed from
the data set, and finally the data set contains 3221 diseases and 3187 disease genes
3.3 Results and discussion
3.3.1 Threshold selection
In this study, we define three thresholds: Γ1, Γ2 and k. The first two thresholds are used to determine
whether a gene is a non-disease gene. We empirically set them as 5 and 4, respectively. The third threshold
k determines the minimum number of neighbors around each node in Gdif . This value controls the number
of edges in Gdif , which will further affect the selection of non-disease genes. We choose k from 3 to 9, and
perform a sensitivity analysis. Fig. 3.4 depicts the results of the analysis for all three disease data. We can
see that the AUC of dgSeq is varying with respect to the threshold k. We choose k = 5 in the study because
the algorithm performs best with this threshold in terms of AUC.
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Figure 3.5: The ROC curves of three algorithms in predicting BC-related genes
3.3.2 The results of AUC values
Fig. 3.5, 3.6 and 3.7 show the ROC curve of the three algorithms in predicting BC-associated, TC-associated
and AD-associated genes with the same sets of benchmark genes, respectively. For BC, dgSeq obtains an
average AUC value of 0.88, whereas the two competing (2Step and Re-balanced) methods only achieve 0.81
and 0.83, respectively. For TC, the AUC values of the two competing algorithms are smaller than 0.80,
which is less than 0.83 from our dgSeq. For AD, dgSeq obtains an average AUC values of 0.80 while the
AUC values of the two competing algorithms are around 0.5. It is worth noting that the two competing
methods were developed to predict cancer-associated genes, which is the reason why their performance in
AD is almost like random. However, their principle allows them to predict non-cancer disease genes such as
AD. In a word, dgSeq outperforms the two competing methods in the experiments.
3.3.3 Enrichment analysis
To further evaluate our algorithm, we rank the unknown genes with dgSeq and perform GSEA on the top
100 genes regarded as potential new disease genes. We also perform the same analysis on the top 100 ranked
genes reported by Endeavor. The size of gene universe in GSEA is 26,533. The enriched pathways are ranked
by their corresponding P-values in ascending order, and the top 10 enriched pathways are listed in Tables
3.1, 3.2, 3.3 for BC, TC and AD, respectively.
Among the ten pathways in Table 3.1, candidate BC disease genes reported by dgSeq are enriched in
six cancer-related pathways: the “Thyroid hormone signaling pathway”, “TGF-beta signaling pathway”,
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Figure 3.6: The ROC curves of three algorithms in predicting TC-related genes
“Epstein-Barr virus infection”, “Pathway in cancer”, “Breast cancer” and “Hepatitis B”. The “Thyroid
hormone signaling pathway” contains multiple thyroid hormone receptor (TR) isoforms, the mutation of
which may lead to various kinds of cancers, such as thyroid cancer and breast cancer [171, 172]. “TGF-beta
signaling pathway” is related to breast cancer because TGF-β1 was found to be linked with increased tumor
progression and cancer invasiveness in late stages of breast cancer. Several drugs against TGF-β1 have also
been developed to treat breast cancer [173]. “Epstein-Barr virus infection” pathway affects the infection
of Epstein-Barr virus (EBV), which has strong connection with breast cancer [174]. Research has shown
that EBV may accelerate the development of malignant breast cancer [175]. “Pathways in cancer” has been
targeted for many drugs, as well as “Breast cancer” pathway. “Hepatitis B” pathway controls another kind
of virus infection which may cause breast cancer [176]. Interestingly, the “Longevity regulating pathway”
is enriched with 5 genes. Although this pathway is not directly related with breast cancer, longevity is a
well-known feature of cancer. Thus, we further analyze the 5 enriched genes and find that 4 of them (SIRT1,
HDAC1, HDAC2, RPS6KB1) have been studied as BC-related genes in previous studies [177, 178, 179].
However, candidate genes reported by Endeavor are only enriched in the “FoxO signaling pathway” with a
P-value of 9.98 × 10−1. Although this pathway is related with breast cancer, the P-value of the analysis is
much lager than the P-values of the pathways enriched by the top 100 genes reported by dgSeq.
From the results of GSEA for TC in Table 3.2, all the 10 pathways are cancer-related. Among these
pathways, the “PI3K-Akt signaling pathway” plays a pivotal role in many key cellular processes, and thyroid
cancer has been shown to be highly associated to this pathway in previous studies [180]. The “FoxO signaling
pathway” is also correlated with many cancers, and one of the genes on this pathway (FOXO3) is reported
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Figure 3.7: The ROC curves of three algorithms in predicting AD-related genes
to be a driver gene of thyroid cancer [181]. Similar to BC, the reported candidate genes are also enriched in
the “Prostate cancer” pathway and “Pathways in cancer”. Because thyroid cancer and prostate cancer also
have the same disease genes (BRAF), genes enriched in the “Prostate cancer pathway” might also be related
to thyroid cancer. “Viral carcinogenesis” pathway and “Epstein-Barr virus infection” pathway are virus-
related pathways which are responsible for various cancers, including thyroid cancer [182, 183]. Melanoma
is a severe tumor which has been proved to be related with thyroid cancer [184]. “Hippo signaling pathway”
regulates organ size and tissue homeostasis. Its fundamental importance make its malfunction leading to
many cancers, such as breast cancer [185]. Although thyroid cancer has not been proved to be related with
“Hippo signaling pathway”, its relationship with breast cancer make us believe that the genes enriched by
“Hippo signaling pathway” might also be related to thyroid cancer. Similar to prostate cancer, lung cancer
and thyroid cancer have two identical disease genes (STRN, KRAS), which make the genes enriched by “Non-
small cell lung cancer” pathway have possibilities to be related with thyroid cancer. Likewise, candidate TC
disease genes reported by Endeavor are only enriched by one pathway: “Colorectal cancer”. The P-value of
the analysis is 9.97× 10−1, which is still much larger than the average P-values of dgSeq’s results.
According to the pathways in Table 3.3, candidate AD disease genes reported by dgSeq are enriched
in seven AD-related pathways: “NOD-like receptor signaling pathway”, “Neurotrophin signaling pathway”,
“GnRH signaling pathway”, “Herpes simplex infection”, “cAMP signaling pathway”, “Inflammatory medi-
ator regulation of TRP channels” and “cGMP-PKG signaling pathway”. Amongt these seven pathways,
“NOD-like receptor signaling pathway” contains NOD-Like receptors which have been demonstrated to be
associated with many diseases, including AD [186]. Neurotrophins are small proteins critical for neuronal
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Table 3.1: Enriched KEGG pathways of candidate genes in the BC dataset
Enriched KEGG pathway Number of Genes P-value
dgSeq
Cell cycle 15 0
Thyroid hormone signaling pathway 10 9.96× 10−3
TGF-beta signaling pathway 9 7.91× 10−3
Epstein-Barr virus infection 12 2.2× 10−2
Pathways in cancer 18 2.2× 10−2
HTLV-I infection 9 3.82× 10−2
Longevity regulating pathway 5 5.54× 10−2
Breast cancer 11 7.28× 10−2
Hepatitis B 10 1.48× 10−1
Adherens junction 5 1.15× 10−1
Endeavor
FoxO signaling pathway 27 9.98× 10−1
growth, and Neurotrophin signaling via BDNF/TrkB-TK+ has strong connection with AD [187]. “GnRH
signaling pathway” is related to AD because GnRH affect Alzheimer’s disease through its marker Aβ protein
[188]. In addition, “Herpes simplex infection” has been implicated as a main factor in AD [189]. “cGMP-
PKG” and “cAMP/PKA” cooperate to control long-term memory which is affected by AD [190, 191]. Finally,
TRP channels mediate physiological responses and research showed that analyzing the connections between
TRP channels and AD may lead to new drugs [192]. Candidate genes reported by Endeavor are enriched
in five AD-related pathways: “Alzheimer’s disease”, “Prion diseases” [193], “Chemokine signaling pathway”
[194], “Phospholipase D signaling pathway” [195] and “VEGF signaling pathway” [196].
Although the number of enriched pathways of Endeavor is less than dgSeq, Endeavor performs better
than dgSeq in terms of the P-value. This result may be caused by the following two reasons. First, only
9 AD case subjects are contained in the data sets. Then, some of the disease genes may not contribute to
the disease in these subjects, and rewiring information obtained from these subjects are not comprehensive.
Disease genes that are not active in the case subjects may be predicted as non-disease genes, which affect
the overall performance of dgSeq. Second, unlike cancers, which have been found to be associated with vast
amount of rewiring in co-expression networks [197, 198], the expression level of genes in AD is much lower
than that of cancers, making dgSeq hard to capture valuable rewiring information from PCC. One possible
solution is to replace PCC with mutual information (MI) when computing the dependence between two
genes as MI can measure linear and nonlinear dependence at the same time, while PCC only measures linear
dependence. Thus, in the future we may use MI instead of PCC to improve the performance of dgSeq.
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Table 3.2: Enriched KEGG pathways of candidate genes in the TC dataset
Enriched KEGG pathway Number of Genes P-value
dgSeq
FoxO signaling pathway 12 0
PI3K-Akt signaling pathway 23 0
Prostate cancer 13 0
Pathways in cancer 21 1.92× 10−3
Viral carcinogenesis 23 5.65× 10−3
Epstein-Barr virus infection 21 1.09× 10−2
Melanoma 9 1.3× 10−2
Hippo signaling pathway 10 1.36× 10−2
Oocyte meiosis 14 1.57× 10−3
Non-small cell lung cancer 9 1.69× 10−2
Endeavor
Colorectal cancer 17 9.97× 10−1
3.3.4 Top 10 unknown genes
Table 3.4 lists the top 10 unknown genes in the ranked lists of BC and TC, respectively. We search these
top 10 unknown genes online, and find that most of them have been studied as disease genes in previous
research. For those not verified as disease genes, we leave their functions blank. From Table 3.4, we can see
that 8 out of 10 genes obtained from the BC data set, 6 out of 10 genes obtained from the TC data set and 6
out of 10 genes obtained from AD data set are potential disease genes which have been studied in literature.
This analysis reveals that the results of our algorithm are in concert with other existing studies, suggesting
that dgSeq is a valuable computational method for discovering new disease genes.
3.4 Conclusion
In this study, we have presented a disease gene prediction method which combines PPI network, clinical RNA-
seq data and OMIM data. The method first constructs a differential network based on rewiring information
computed from case and control clinical RNA-Seq data. A DGN is constructed based on OMIM database.
Then, the set of non-disease genes is selected from the DGN and the differential network according to the
shortest path theory. Finally, features of these non-disease genes and known disease genes are extracted from
the PPI network and the differential network, and used to train a logistic classifier, which is then employed
to predict disease genes.
Evaluations conducted on data sets of two cancers and Alzheimer’s disease reveal that our algorithm
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is overall more effective than previous methods. Further analysis on the top predicted disease genes have
also proved that dgSeq is powerful for predicting new disease genes. In the future, we would integrate more
omics data into the disease gene prediction method and improve the performance of dgSeq in predicting new
disease genes. We can also replace PCC with MI and extend the strategy for capturing network rewiring
information in different types of biomolecular networks to enhance dgSeq’s performance in various types of
diseases.
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Table 3.3: Enriched KEGG pathways of candidate genes in the AD dataset
Enriched KEGG pathway Number of Genes P-value
dgSeq
NOD-like receptor signaling pathway 7 1.21× 10−2
Neurotrophin signaling pathway 6 4.82× 10−2
HTLV-I infection 8 1.27× 10−1
Influenza A 5 1.33× 10−1
GnRH signaling pathway 6 3.05× 10−1
Herpes simplex infection 6 3.41× 10−1
cAMP signaling pathway 9 3.92× 10−1
Inflammatory mediator regulation of 6 3.98× 10−1
TRP channels
Epstein-Barr virus infection 11 4.41× 10−1
cGMP-PKG signaling pathway 6 4.43× 10−1
Endeavor
Th1 and Th2 cell differentiation 11 1.96× 10−3
Alzheimer’s disease 11 2.09× 10−3
Prion diseases 5 1.91× 10−2
Influenza A 7 1.98× 10−2
Chemokine signaling pathway 10 2.49× 10−2
Phospholipase D signaling pathway 6 2.66× 10−2
T cell receptor signaling pathway 12 2.68× 10−2
Leishmaniasis 5 3.37× 10−2
VEGF signaling pathway 10 3.57× 10−2
Endocrine resistance 19 3.91× 10−2
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Table 3.4: Top 10 unknown genes
Gene Name Function Reference
BC
UBB Potential disease gene [199]
SKP2 Potential Oncogene [200]
KAT5
HDAC1 Potential disease gene [178]
RARA Potential therapeutic target [201]
HDAC2 Potential disease gene [178]
HDAC3 Potential disease gene [178]
CDK8 Potential Biomarkers [202]
MED1 Potential therapeutic target [203]
SMARCC1
TC
HSP90AA1
XPO1 Potential disease gene [204]
YWHAB
MDM2 Oncogene [205]
MAX
PPP2CA Disease gene for many cancer [206]
EGFR Potential marker [207]
GRB2 Potential disease gene [208]
RB1 Potential disease gene [209]
UBE2I
AD
RNF32
MAST1 Potential disease gene [210]
CSNK1A1
HSPA5 Poteintial target [211]
PPP5C Potential disease gene [212]
PPP1CA Potential disease gene [212]
CAMK2A Disease gene [213]
RBBP4 Potential disease gene [214]
ATP5A1
H2AFX
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In addition to non-disease gene selection, another issue that limits the accuracy of computational predic-
tion is the quality of the PPI networks. Since PPI is dynamic and tissue-specific, directly using static PPI
networks might affect the performance of the algorithms. In this chapter, sample-based networks constructed
based on the clinical gene expression data are proposed. These networks consist of those significant genes
associated with the disease under consideration, which are more valuable than the original static networks.
Meanwhile, an ensemble strategy is used to guarantee that all the disease genes could be predicted. This
chapter fulfills Objective 3 of this thesis.
Abstract
Disease gene prediction is a critical and challenging task. Many computational methods have been developed
to predict disease genes, and protein-protein interaction (PPI) network is widely used to predict disease genes.
However, existing methods commonly use a universal static PPI network, which ignore the fact that PPIs
are dynamic, and PPIs in various patients should also be different. To address these issues, we develop an
ensemble algorithm to predict disease genes from clinical sample-based networks (EdgCSN). The algorithm
first constructs single sample-based networks for each case sample of the disease under study. Then, these
single sample-based networks are merged to several fused networks based on the clustering results of the
samples. After that, logistic models are trained with centrality features extracted from the fused networks,
and an ensemble strategy is used to predict the final probability of each gene being disease-associated.
EdgCSN is evaluated on breast cancer (BC), thyroid cancer (TC) and Alzheimer’s disease (AD) and obtains
AUC values of 0.970, 0.971 and 0.966, respectively, which are much better than the competing algorithms.
Subsequent de novo validations also demonstrate the ability of EdgCSN in predicting new disease genes.
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4.1 Background
Disease gene prediction is a critical yet challenging task. It helps us understand the mechanisms of diseases,
find therapeutic targets, and develop novel treatment strategies [215]. During the past decades, disease gene
prediction has gained great development. Many computational algorithms have been developed to predict
disease genes so that the cost and time for in-depth validation could be maximal reduced.
Among the various types of data that have been used to predict disease genes, protein-protein interactions
(PPIs) are the most widely used evidence. On the one hand, interacting proteins (genes) usually have similar
functions, which means algorithms can predict new disease genes based on their relationships with known
disease genes in the PPI network. On the other hand, due to the network property of PPIs, most network
analysis algorithms can be used to predict disease genes from PPI networks. For example, earlier methods,
such as RWR, performed the random walk on PPI networks to predict disease genes [18]. Gillis et al. used
degree centralities to rank all the genes [216].
However, PPIs are dynamic during the life time of cells, and not all PPIs exist in all the tissues. Static
PPI networks downloaded from online databases contain lots of false positives which limit the performance
of the methods that directly use them [217]. Thus, many studies integrate static PPI networks with disease-
related data, such as GWAS and gene expression data, to improve the prediction accuracy [218, 58, 219].
This leads to two types of approaches. The first type of approach weights PPI networks with disease-related
data, and predicts candidate genes from the weighted networks. For instance, Wang et al. searched dense
modules from a PPI network weighted by gene expression and GWAS data [58]. Our previous study trained
a regression model with features extracted from a PPI network weighted by differential co-expression [158].
The second type of approach constructs heterogeneous networks and combines them with PPI networks
to enhance the prediction. For example, Chen et al. combined gene co-expression networks and pathway
coexist networks with PPI networks to predict disease genes [117, 118]. Singh-Blom et al. trained a biased
SVM with features extracted from phenotype-phenotype networks and PPI networks [220] to predict disease
genes. Despite their success, the discussed approaches still use PPI networks with false positive interactions,
which contain inaccurate topological structures. PPI networks downloaded from different databases might
affect the prediction results.
To solve these issues, in our previous study, gene expression data of clinical samples have been used to
construct sample-specific PPI networks [43]. Each single sample-based network only contains the significant
PPIs associated with the disease under consideration, which reduces the false positive interactions. A
network that fuses all the single sample-based networks was used to predict the disease-associated genes,
so that disease genes that function in different patients could all be identified. In this study, to further
extend our research, an ensemble algorithm that predicts disease genes from clinical sample-based networks
(EdgCSN) is proposed. Meanwhile, Katz centrality is used instead of edge clustering coefficient to better
extract local structural information from the sample-based networks.
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4.2 Methods
Fig. 4.1 depicts the work flow of EdgCSN which is explained as follows. (a)-(b). A single sample-based
network is constructed for each case sample by combining clinical samples and the universal static PPI
network. (c). The case samples are clustered into a few groups and single sample-based networks of the
samples in the same group are fused to one network. (d). A logistic model is trained by the centrality
features extracted from each fused network, and the probability of each gene being disease-associated is
predicted. (e). The maximum probability of a gene calculated from all the logistic models is regarded as its
probability of being disease-associated. In the following subsections, details of the five steps in Fig. 4.1 are
first discussed. Then, the data sources and evaluation metrics are explained.
(a)
(c) Fused network
(d) Logistic regression
(e) Probability
Single sample-based network(b)
Figure 4.1: Work flow of the algorithm.
4.2.1 Sample-based networks
To obtain the most informative PPIs and remove the false positive ones, sample-based networks are used
in this study instead of the universal static PPI networks. In addition, since the real caustic genes of
different patients may not be the same, case samples are divided into different clusters so that patients with
distinct conditions are analyzed separately. Specifically, three steps are performed to obtain the sample-based
networks.
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1. A single sample-based network is constructed for each case sample;
2. Case samples are classified into different clusters;
3. Networks of the samples in the same cluster are fused together.
For the first step, we assume that a PPI exists in a single sample-based network Ns only if the two
interacted proteins are both activated in sample s. Concretely, a gene i in a case sample s is considered
being activated if
mcase[i, s] ≥ λ ∗mean(mcntl[i]) (4.1)
where mcase[i, s] is the expression value of gene i in sample s, and mean(mcntl[i]) is the mean expression
value of gene i over all control samples. To construct Ns, every edge (i, j) in the static PPI network is
validated and only the one with both i and j being activated is added to Ns. Then, S single sample-based
networks are constructed for the S case samples.
For the second step, hierarchical clustering is used to classify case samples into different clusters. Given
two samples s1 and s2, their pairwise distance is calculated by
dist(s1, s2) = 1− (s1 − s¯1) · (s2 − s¯2)‖s1 − s¯1‖2‖s2 − s¯2‖2 (4.2)
where s1 (s2) is a vector of expression values of genes in sample s1 (s2), and s¯1 (¯s2) is the corresponding
average expression value. During the bottom-up process, the distance between two newly formed clusters u
and v is computed as follows
Distance(u, v) = max
p∈u,q∈v(dist(p, q)) (4.3)
which is the maximum distance between samples in u and v. Let dmax denote the maximum distance among
clusters, 0.7 ∗ dmax is used as the threshold to select clusters from the resulted dendrogram.
For the third step, assuming all the S samples are classified into l clusters and the t-th cluster contains
St samples, we have S =
∑l
t=1 St. The objective is to fuse the networks of the samples in the same cluster
into one network. Although many network fusion methods have been published [221], most of them cannot
efficiently fuse complex PPI networks, especially when the number of networks to be fused is more than
1, 000. Thus, we propose a simple strategy which uses a threshold  to determine whether an edge exists in
the fused networks. An edge (i, j) is considered as significant only if it appears in at least  single sample-
based networks. Precisely, given a cluster with St samples, let fij be the number of times edge (i, j) appears
in the St single sample-based networks. When fij < , (i, j) is not included in the fused network, and when
fij ≥ , (i, j) is in the fused network. Finally, l fused networks are obtained for the l clusters, respectively.
4.2.2 Model design
Given a biomolecular network, if disease genes are labeled as 1 and non-disease genes are labeled as 0,
the disease gene prediction problem can then be formulated as a network labeling problem [46]. Let x =
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(x1, x2, . . . , xH) denote a set of binary labels of all the H genes in the biomolecular network. x is known as
the configuration of the network, and the set X of all possible configurations is a random field. Based on our
previous studies [47, 118, 158], a generalized model was proposed in [43] which predicted the probability of
a gene i being labeled as 1 by
P (xi = 1|x[−i], θ) = exp(θφi)
1 + exp(θφi)
(4.4)
where θ is a parameter vector and φi is the feature vector of gene i extracted from the biomolecular network
labeled by a prior configuration x.
In [43], φi is a 7-dimensional feature vector which consists of a dummy feature (1) and three pairs of 0-1
centrality features: 0-1 degree centrality, 0-1 closeness centrality and 0-1 edge clustering coefficient. These
three 0-1 centrality indices have shown their ability in characterizing discriminative features for classifying
disease and non-disease genes. However, edge clustering coefficient can only capture the structural informa-
tion between genes and their direct neighbors, and the relations between genes and their k-th order (k ≥ 2)
neighbors cannot be obtained. Since proteins usually form a complex or functional module to achieve a
specific function [217], the k-th order neighbors should also be considered when the local structural infor-
mation is extracted. Previous study also showed that the indirect neighbors were useful for disease gene
prediction [48]. Thus, we replace edge clustering coefficient by Katz centrality in this study to leverage the
local structure information between nodes and their higher order neighbors.
Given a labeled network N = (V,E), V is the set of nodes and E is the set of edges, the 0-1 degree
centrality denoted by Cdi0 and C
d
i1 are defined as follows
Cdi0 =
∑
(i,j)∈E
(1− xj), Cdi1 =
∑
(i,j)∈E
xj (4.5)
The 0-1 closeness centrality denoted by Cci0 and C
c
i1 are defined as
Cci0 =
1
n0 − 1
∑
j∈V,j 6=i
1
dsp(i, j)
(1− xj),
Cci1 =
1
n1 − 1
∑
j∈V,j 6=i
1
dsp(i, j)
xj
(4.6)
where dsp(i, j) is the length of the shortest path between node i and j, n0 and n1 are the number of nodes
labeled as 0 and 1, respectively
Katz centrality measures the relative influence of a node in the network [222]. It is defined by
Ci =
∞∑
k=0
n∑
j=1
αk(Ak)ji (4.7)
where A is the adjacency matrix of the network, k is the length of the path between i and j, α is a damping
factor penalizes the impact node j on i. The longer the path, the smaller the impact node j is on i.
When α is properly chosen, Eq. (4.7) will converge. However, when Katz centrality is used in this study,
we care more about the information conveyed by paths with short distance (less than 5). Study in link
52
prediction also showed that k = 3 or k = 4 can yield satisfactory performance [223]. Thus, α and k are
chosen by grid search without the proof of convergence.
In previous studies, Katz centrality calculated from heterogeneous networks had been used to prioritize
disease genes [220]. However, results of directly using Katz centrality were not better than existing methods,
such as RWR [18]. To make Katz centrality suitable for disease gene prediction, we define the 0-1 Katz
centrality as follows:
Ci0 =
∞∑
k=0
n∑
j=1
αk(Ak)ji(1− xj),
Ci1 =
∞∑
k=0
n∑
j=1
αk(Ak)jixj
(4.8)
Similar to 0-1 degree and 0-1 closeness centrality, the 0-1 Katz centrality measures the importance of a
gene among disease genes and non-disease genes, respectively, which is more appropriate for disease gene
prediction. The new feature vector of each gene is then defined as
φi = (1, C
d
i0, C
d
i1, C
c
i0, C
c
i1, Ci0, Ci1) (4.9)
4.2.3 Network labeling and benchmark selection
As discussed in the previous section, biomolecular networks are needed to be labeled by a prior configuration
so that disease genes can be predicted. In this study, we use the l fused networks to predict disease genes,
which means the known disease genes in these networks are labeled as 1 while other genes are labeled as 0.
Then, the feature vectors of all genes can be extracted by Eq. (4.9).
In addition, to train the logistic models used for prediction, we also need a set of non-disease genes,
which are used as negative instances. Unfortunately, no databases contain non-disease genes. Therefore, our
previous strategy proposed in [78] is used to select the non-disease genes used in the training.
In [78], a disease gene network (DGN) was constructed with the disease-gene association data downloaded
from OMIM [80]. In the DGN, each node is either a disease or a disease-associated gene. Diseases are
connected with their associated genes, and two diseases are connected if they share one or more associated
genes. Thus, diseases that are close to each other in the DGN have more chances to share similar disease
genes, which means they are more likely to have similar mechanisms. If the length of the shortest path
between two diseases is larger than a threshold η, they might not have similar mechanisms, and the disease
genes of one disease could be regarded as non-disease genes of the other disease. With this strategy, a group
of non-disease genes are obtained for the disease under study, and only non-disease genes that exist in all
the l fused networks are selected. η = 5 is chosen based on our previous experience.
Assuming m disease genes are known to be associated with the disease under study, we randomly select
m genes from the set of non-disease genes, and these 2m genes form a set of gold standard genes. This
process is performed 50 times and finally we obtain 50 sets of gold standard genes and regarded them as
benchmarks.
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4.2.4 Ensemble prediction
Given m disease genes and m non-disease genes, features of these genes extracted from the l fused networks
are used to train l logistic models, respectively. Equation (4.4) is then used to predict the probability of
each gene being disease-associated in each fused network.
For each gene, l
′
(1 ≤ l′ ≤ l) probabilities are calculated. Considering that the caustic genes of different
samples might be different, the obtained probabilities only reveal the potential of the gene being disease-
associated in the corresponding clusters. Thus, for each gene, the ensemble strategy chooses the maximum
value of the l
′
probabilities as its probability of being disease-associated.
4.2.5 Datasets
In this study, datasets of breast cancer (BC), thyroid cancer (TC) and Alzheimer’s disease (AD) are used
to evaluate the algorithm. The BC-associated genes and TC-associated genes are obtained from the Cancer
Gene Census category (http://cancer. sanger.ac.uk/census#) [87]. In total, 35 BC-associated genes and 33
TC-associated genes are used as the benchmarks. The AD-associated genes are obtained from MalaCards:
The human disease database (http: //www.malacards.org/). The database contains 182 potential AD
associated genes ranked by their probability of being AD-associated in descending order. 39 of the first 50
genes exist in the static PPI network are used as benchmarks.
The gene expression data of BC and TC are downloaded from NCI Genomic Data Commons (GDC)
[104], which measures the data by RNA-Seq. We download the data normalized by FPKM (Fragments Per
Kilobase Million) and transform them to TPM (Transcripts Per Kilobase Million) by the strategy proposed
in [224]. The expression data of Alzheimer’s disease (AD) are downloaded from Gene Expression Omnibus
(GSE53697) [168], which are also measured by RNA-seq. The data normalized by RPKM (Reads Per Kilobase
Million) are downloaded and transformed to TPM with the same strategy used for the data downloaded from
GDC. TPM is chosen because it facilitates the comparison of the proportion of reads that are mapped to a
gene in each sample and is usually better than FPKM and RPKM in cross-sample comparison, which helps
us properly cluster all the samples. In total, the dataset of BC contains 1102 case samples and 113 control
samples; the dataset of TC contains 502 case samples and 58 control samples; the dataset of AD contains 9
case samples and 8 control samples.
After downloading the gene expression data, four steps are performed to control the genes used in our
study. (1). TPM values less than 1 are replaced by 0 because of the unreliability. (2). log2(TPM+1) is used
instead of the original TPM values. (3). Genes expressed in less than 10% of samples (case and control) are
removed. (4). Genes not existing in the PPI network are removed. In total, 14436 genes, 13959 genes and
13370 genes are left for BC dataset, TC dataset and AD dataset, respectively.
The static PPI network is downloaded from the InWeb InBioMap database (version 2016 09 12) [170].
The database consists of more than 600,000 protein interactions collected from eight source databases, which
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insures that valuable protein interactions are not missed during the construction of the sample-based PPI
networks. In this study, the proteins in the PPI network are mapped to their corresponding genes to form
a gene-gene interaction network. In the paper, the term “PPI network” is used to represent the gene-gene
interaction network because of simplicity.
4.2.6 Evaluation metrics
In this study, a disease gene is regarded as positive while a non-disease gene is regarded as negative. Given
a threshold Γ, a gene i with a probability pi ≥ Γ is predicted as positive, and otherwise it is predicted as
negative. For all genes in the benchmark, the true positives (TP), false positives (FP), true negatives (TN),
and false negatives (FN) are defined as follows
1. TP : a disease gene is predicted as a disease gene
2. FP : a non-disease gene is predicted as a disease gene
3. TN : a non-disease gene is predicted as a non-disease gene
4. FN : a disease gene is predicted as a non-disease gene
Then, we can calculate the true positive rate (TPR) and the false positive rate (FPR) of the prediction
results by the following equations
TPR =
TP
TP + FN
, FPR =
FP
TN + FP
(4.10)
To evaluate the algorithm, the receiver operating characteristic (ROC) curve is created by plotting the
TPR against FPR with various Γ. The area under the ROC curve (AUC) is also used to evaluate the overall
performance of the algorithm.
Since the number of genes used as benchmark is small, leave-one-out cross validation (LOOCV) is per-
formed to calculate the probabilities of genes in the benchmark being disease-associated. With the 50 sets
of gold standard genes, LOOCV is performed 50 times. In each round, the probabilities of the 2m genes
being disease-associated are calculated, as well as the AUC value. The average AUC value is then used to
evaluate the algorithm.
In addition, de novo validation is performed by ranking all the unknown genes in descending order by
their average probabilities calculated by the models trained with the 50 sets of gold standard genes. The top
10 unknown genes are analyzed from published literature to illustrate the ability of EdgCSN in predicting
new disease genes.
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4.3 Results
4.3.1 Clustering
Figs. 4.2, 4.3 and 4.4 show the dendrograms of the hierarchical clustering. BC and TC samples are divided
to three clusters and AD samples are divided to two clusters. Thus, three fused networks are constructed
for BC and TC, respectively, and two fused networks are constructed for AD.
Figure 4.2: Hierarchical clustering dendrogram for BC.
Figure 4.3: Hierarchical clustering dendrogram for TC.
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Figure 4.4: Hierarchical clustering dendrogram for AD.
4.3.2 Sensitivity analysis
The performance of our algorithm is affected by four hyperparameters: λ, , α and k. The first two control
the resulted fused networks. Based on our previous study, edges that exist in more than three networks
were significant [43]. Thus,  = 3 is empirically chosen in this study. As for λ, since the RNA-seq data
are normalized by TPM rather than DESeq2 [169], λ is searched from a new set {1.0, 1.1, 1.2, 1.3, 1.5},
which is different from the one obtained in our previous study. The other two hyperparameters control the
information extracted by Katz centrality. To obtain the appropriate hyperparameters, α is searched from
{0.1, 0.2}, and k is searched from {1, 2, 3, 4}, respectively.
Tables 4.1, 4.2 and 4.3 show the results of the grid search for BC, TC and AD, respectively. EdgCSN
performs best for BC when λ = 1.1, α = 0.2, k = 2 with an AUC = 0.970; for TC when λ = 1.11, α = 0.1, k =
2 with an AUC = 0.971; for AD when λ = 1.0, α = 0.2, k = 2 with an AUC = 0.966. ‘-’ denotes that more
than 10% known disease genes are not contained in the fused networks constructed by the corresponding
hyperparameters.
All the three experiments obtain their best AUC values when k = 2, and a smaller or higher k would
significantly affect the performance of the algorithm. These results indicate that local structural information
contained within the second order neighborhood is valuable for disease gene prediction. Other disease gene
prediction algorithms that use topological structure of biomolecular networks could also further include these
information to improve their prediction.
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Table 4.1: Sensitivity analysis. The resulted AUC values obtained with different combinations of
hyperparameters for BC.
k
λ α 1 2 3 4
1.0 0.1 0.867 0.961 0.873 0.878
1.0 0.2 0.869 0.966 0.889 0.870
1.1 0.1 0.883 0.967 0.890 0.903
1.1 0.2 0.881 0.970 0.909 0.896
1.2 0.1 0.845 0.957 0.877 0.898
1.2 0.2 0.846 0.958 0.892 0.894
1.3 0.1 0.787 0.938 0.819 0.842
1.3 0.2 0.787 0.940 0.841 0.842
1.5 0.1 0.777 0.938 0.813 0.775
1.5 0.2 0.777 0.938 0.786 0.816
4.3.3 Comparison
EdgCSN is compared with three algorithms: the Re-balanced algorithm of Chen et al. [118], the AIDG
algorithm of Tang et al. [79], and our previous algorithm dgCSN [43]. Re-balanced method combined multiple
types of biomolecular networks to predict cancer-related genes, and AIDG used sub-cellular localization to
purify universal PPI networks. These algorithms have been shown better than many classical methods, such
as the RWR method [18], the DIR method [225] and the ToppNet [226].
The resulted ROC curves for BC, TC, and AD are depicted in Figs. 4.5, 4.6, 4.7, respectively. The
AUC values of EdgCSN for BC, TC and AD are 0.970, 0.971 and 0.966, respectively, which are much better
than those of the competing algorithms. For BC, our EdgCSN is 7% more accurate than the competing
algorithms, and for TC and AD, EdgCSN is 20% more accurate than the other three algorithms.
4.3.4 De novo validation
To validate the performance of EdgCSN in predicting new disease genes, unknown genes are ranked in
descending order by their average probabilities of being disease-associated predicted by the 50 sets of genes
in the benchmark. The top 10 predictions are further searched in existing literature to find out if they are
associated with the disease under study.
Table 4.4 shows the top 10 predictions of the three diseases. Functions of the genes that have not been
studied in existing literature are left blank. Most of the genes have been analyzed as disease-associated
in existing studies, especially for BC, where all the 10 genes have been studied in the existing literature.
For TC, although only 5 of the 10 genes have been studied, 3 of the 5 genes that have not been studied
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Table 4.2: Sensitivity analysis. The resulted AUC values obtained with different combinations of
hyperparameters for TC.
k
λ α 1 2 3 4
1.0 0.1 0.716 0.966 0.839 0.790
1.0 0.2 0.713 0.967 0.795 0.802
1.1 0.1 0.729 0.971 0.800 0.746
1.1 0.2 0.728 0.969 0.744 0.779
1.2 0.1 0.809 0.954 0.748 0.776
1.2 0.2 0.808 0.953 0.652 0.792
1.3 0.1 0.621 0.962 0.779 0.786
1.3 0.2 0.620 0.960 0.662 0.794
1.5 0.1 0.412 0.965 0.809 0.720
1.5 0.2 0.411 0.963 0.645 0.679
(‘CEP72’, ‘CEP131’ and ‘GPR83’) belong to the Centrosomal Protein family and G Protein-coupled Receptor
respectively. Many proteins belong to these families are closely related to cancers [227], which means ‘CEP72’,
‘CEP131’ and ‘GPR83’ might be predicted as being TC-associated in the future.
4.4 Discussion
Many algorithms have been proposed to predict disease genes, and most of them rely on PPI networks
to achieve the prediction. However, PPI is dynamic and tissue-specific, static PPI networks downloaded
from online databases contain many false positives, and directly using them would limit the accuracy of
disease gene prediction. Moreover, for patients with a specific disease, their disease states might be driven
by different subset of disease genes, and analyzing their data together might affect the identification of rarely
mutated disease genes .
Therefore, in this study, an ensemble algorithm is proposed to predict disease genes from clinical sample-
based networks. The algorithm first constructs single sample-based networks by combining clinical samples
and a universal static PPI network. A group of networks which contain disease-related PPIs are generated.
Then, case samples are divided into different clusters and networks belong to the samples in the same cluster
are merged together. This step allows patients with similar causing genes to be analyzed together. After
that, 0-1 centrality features extracted from the fused networks are used to train the logistic models that
calculate the probability of each genes being disease-associated in each fused network. Finally, an ensemble
strategy is performed by choosing the maximum probability obtained from different fused networks as the
final probability of a gene being disease-associated.
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Table 4.3: Sensitivity analysis. The resulted AUC values obtained with different combinations of
hyperparameters for AD.
k
λ α 1 2 3 4
1.0 0.1 0.808 0.964 0.809 0.763
1.0 0.2 0.809 0.966 0.764 0.705
1.1 0.1 0.665 0.956 0.757 0.685
1.1 0.2 0.665 0.957 0.596 0.636
1.2 0.1 0.564 0.938 0.809 0.605
1.2 0.2 0.563 0.939 0.608 0.596
1.3 0.1 0.508 0.914 0.810 0.674
1.3 0.2 0.508 0.914 0.608 0.614
In the experiments conducted on BC, TC and AD, our EdgCSN is much better than the competing
algorithms in terms of AUC scores. Further analysis of the top 10 unknown genes also illustrate that
EdgCSN is capable of predicting novel disease genes. Our study has provided insight into how clustering
patient samples might improve the prediction of disease genes.
4.5 Conclusions
Our EdgCSN use ensemble learning to predict disease genes from clustered sample-based networks. In the
future, the strategies used for clustering can be further improved. For instance, Eq. (4.2) uses the expression
data of all the genes to calculate the pairwise distances, and the results might be dominated by non-disease
genes. We could reduce the number of genes used for clustering and choose those differentially expressed
genes or marker genes that are associated with a specific subtype. These subsets of genes should improve
the clustering results as well as the final prediction.
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Figure 4.5: ROC curves for BC.
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Figure 4.6: ROC curves for TC.
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Figure 4.7: ROC curves for AD.
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Table 4.4: Top 10 unknown genes
Gene Name Function Reference
BC
CREBBP Potential disease gene [228]
NBN Potential disease gene [229]
PARP1 Potential biomarker [230, 231]
NCOR2 Potential biomarker [232]
RXRA Potential therapeutic target [233]
WRN Potential disease gene [234]
EXO1 Potential disease gene [235]
NCOA3 Potential disease gene [236]
RMI2 Potential disease gene [237]
TOPBP1 Potential therapeutic target [238]
TC
HRAS Potential disease gene [239]
HAUS7
CEP72
GTF2I Potential disease gene [240]
BCLAF1 Potential disease gene [241]
HAUS3
FGFR1OP Potential disease gene [242, 243]
CEP131
GPR83
ALMS1 Potential disease gene [244]
AD
MAP2 Potential disease gene [245]
DPYSL3
ERRFI1 Potential disease gene [246]
DAB2 Potential disease gene [247]
AMPH Potential disease gene [248]
SYN1 Potential disease gene [249]
SYT9 Potential disease gene [250]
AXIN1
PRNP Potential disease gene [251]
AAK1 Potential disease gene [252]
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5Enhancing the prediction of disease-gene associations with multi-
modal deep learning
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The previous two chapters have proposed strategies to solve the two problems that exist in developing
machine learning-based methods. In this chapter, a deep learning-based method is proposed to fuse multiple
types of data. Specifically, multimodal DBN is used to combine raw features learned from PPI network and
GO data. The model can learn both linear and nonlinear relationships within different types of data, and
extract cross-modality features which are more valuable for disease-gene prediction. This chapter fulfills
Objective 4 of this thesis.
Abstract
Motivation: Computationally predicting disease genes helps scientists optimize the in-depth experimen-
tal validation and accelerates the identification of real disease-associated genes. Modern high-throughput
technologies have generated a vast amount of omics data, and integrating them is expected to improve the
accuracy of computational prediction. As an integrative model, multimodal deep belief net (DBN) can cap-
ture cross-modality features from heterogeneous datasets to model a complex system. Studies have shown
its power in image classification and tumor subtype prediction. However, multimodal DBN has not been
used in predicting disease-gene associations.
Results: In this study, we propose a method to predict disease-gene associations by multimodal DBN (dg-
MDL). Specifically, latent representations of protein-protein interaction networks and gene ontology terms
are first learned by two DBNs independently. Then, a joint DBN is used to learn cross-modality repre-
sentations from the two sub-models by taking the concatenation of their obtained latent representations
as the multimodal input. Finally, disease-gene associations are predicted with the learned cross-modality
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representations. The proposed method is compared with two state-of-the-art algorithms in terms of 5-fold
cross-validation on a set of curated disease-gene associations. dgMDL achieves an AUC of 0.969 which
is superior to the competing algorithms. Further analysis of the top-10 unknown disease-gene pairs also
demonstrates the ability of dgMDL in predicting new disease-gene associations. The Supplementary data
are available at https://doi.org/10.1093/bioinformatics/btz155.
5.1 Introduction
Ever since the discovery of the first disease gene in 1949 [2], thousands of genes have been identified to
be disease-associated. Identifying disease-gene associations helps us decipher the mechanisms of diseases,
find diagnostic markers and therapeutic targets, which further leads to new treatment strategies and drugs.
High-throughput technologies usually predict a few hundreds of candidate genes, and validating all these
candidates requires an extensive amount of cost and time. Thus, a commonly used approach is to first
computationally predict/prioritize candidate genes associated with the diseases under consideration, then
experimentally validate a subgroup of candidates based on the results of computational prediction so that
the yield of the experiments can be greatly improved.
Currently, various types of data have been used to predict disease-gene associations, and protein-protein
interaction (PPI) networks are the most widely used evidence. Previous algorithms tried to predict disease-
gene associations by directly using the topological structure of PPI networks [18, 22]. However, universal
PPI networks downloaded from online databases contain lots of false positives, and only using them cannot
further improve the prediction accuracy. Thus, researchers tend to combine more types of data with PPI
networks to predict disease-gene associations.
One strategy is to combine PPI networks with clinical data which capture the difference between patients
(case) and normal people (control). This resulted in a group of GWAS-based methods [218, 253, 254] and
gene expression (GE)-based methods [54, 58, 78]. GWAS-based methods first map the single-nucleotide
polymorphisms and their corresponding P -values to the human genome. Then, the mapped P -values are
combined with PPI networks and other evidence to predict disease-gene associations. GE-based methods
analyze the expression level of each gene in case and control subjects and identify differentially expressed genes
or rewired co-expressions, which are then combined with PPI networks to predict disease-gene associations.
Although algorithms based on clinical data are more accurate than the previous methods, their perfor-
mance is still limited by the amount and quality of the data. For diseases not well studied, the amount of
available data limits the performance of the algorithms. For other diseases like cancers, although projects
such as TCGA [255] have generated a large amount of omics data, not all disease-gene associations can be
successfully identified because of the following reasons. The tumorigenesis of most patients is associated
with several frequently mutated genes, and clinical data-based algorithms can easily identify the associations
between cancers and these genes. However, for other less mutated genes, the overwhelming abundance of
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frequently mutated genes would make the computational model believe that the less mutated ones are not
disease-associated. As a result, algorithms based on clinical data tend to generate results that do not include
less mutated genes. Therefore, the key issue now is to identify those critical but less mutated genes [256].
To address the problems of existing methods, a generic model which combines different types of non-
clinical data would be more valuable. On the one hand, this model predicts disease-gene associations using
evidence that can reveal the intrinsic properties of diseases and genes, such as disease similarities, gene
similarities, PPI networks, gene ontology (GO) terms, protein domains etc. Integrating such multiple types
of information could complement the shortage of previous PPI-based algorithms. On the other hand, since
clinical data is not used in the prediction, the results are less likely to be affected by the frequency of the
disease-associated mutations.
Methods based on matrix factorization (MF) are generic models and can leverage the disease similarities
and gene similarities to predict disease-gene associations [6, 257, 258]. However, MF-based algorithms usually
need too much time to converge and most of them can only use limited types of data, which limits their
performance. Since studies have shown that integrating multiple types of data could enhance the prediction
of disease-gene associations [46, 48, 118, 70], a good generic model should be able to integrate multiple types
of data with a unified framework so that the advantages of multi-view data can be properly utilized.
Currently, many algorithms have been proposed to integrate multi-view biological data. Among these
algorithms, multimodal deep learning reveals great potential in capturing cross-modality features to uncover
the mechanisms of biological systems [259]. Deep learning algorithms, such as deep belief net (DBN) [260],
have been applied to drug repositioning [261] and cancer subtype prediction [262]. Although these studies
have shown the abilities of deep learning in analyzing biological systems, no studies have used deep learning
in disease gene prediction because of two reasons. First, if deep learning is used to predict the disease genes
of a specific disease, the number of known disease genes would be too small to train a deep model. Second, if
DBN is used to extract features from the biological data, Gaussian units have to be used in the visible layer
so that the model can accept real-valued data. The corresponding restricted Boltzmann machine (RBM) in
the DBN is a Gaussian-Binary RBM (GBRBM), which is hard to train [263, 264]. More attention is needed
to choose appropriate hyperparameters.
To solve the above issues, in this study, instead of predicting associated genes for a specific disease,
we build a generic model to predict disease-gene associations for all known diseases. This strategy greatly
increases the number of positive samples, making it possible to train a deep network. Meanwhile, the
Gaussian visible layer is used to learn latent features from original real-valued features. To leverage the
advantage of deep learning in data fusion and improve prediction accuracy, multimodal DBN is used to fuse
different modalities and obtain joint representations. Specifically, two sub-models are first trained based on
PPI networks and GO terms, respectively. Then, a joint DBN is used to combine the two sub-models to
learn cross-modality representations.
In the rest of the paper, Section 5.2 describes the details of the algorithm and the experiments. Section
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5.3 discusses the results of the evaluation. Section 5.4 draws some conclusions.
5.2 Materials and methods
5.2.1 RBM
RBM is a graphical model which consists of a visible layer and a hidden layer. In this model, every unit in one
layer is connected to every unit in another layer, and there are no within layer connections. Fig. 5.1 shows an
example RBM with four visible units and five hidden units. RBM can characterize the distribution of input
data, and the learned probabilities of hidden units can be used as features to characterize raw data. When
data is binary, the corresponding RBM is a Binary-Binary RBM (BBRBM), and the probability distribution
is defined by the following likelihood function:
P (v) =
∑
h
P (v, h) =
∑
h
e−E(v,h)
Z
(5.1)
where E(v, h) = −bT v− cTh−hTWv is the energy function. Z = ∑v∑h e−E(v,h) is known as the partition
function. W is the weight matrix that connects visible and hidden units. b and c are the biases of visible
and hidden layers, respectively.
RBM can be learned by using the stochastic gradient descent (SGD) on the empirical negative log-
likelihood of training data, which results in the following gradients for a BBRBM [265]
−∂ log p(v)
∂Wij
= Ev[p(hi|v) · vj ]− v(i)j · sigm(Wi · v(i) + ci) (5.2)
−∂ log p(v)
∂ci
= Ev[p(hi|v)]− sigm(Wi · v(i)) (5.3)
−∂ log p(v)
∂bj
= Ev[p(vj |h)]− v(i)j (5.4)
where sigm denotes the sigmoid function sigm(x) = 1/(1 + exp(−x)). These equations compute the expec-
tations over all possible configurations of input data, which is difficult. A feasible solution is to estimate the
expectations with a fixed number of samples. Several sampling techniques have been developed to calculate
the gradients [266, 267, 268]. In this study, we choose the contrast divergence (CD) because of its simplicity.
Details of the algorithms can be found in [266].
Visible 
layer
Hidden 
layer
Figure 5.1: Schematic example of an RBM.
67
For GBRBM, the energy function becomes:
E(v, h) =
∑
i∈vis
(vi − ai)2
2σ2i
−
∑
j∈hid
bjhj −
∑
i,j
vi
σi
hjwij (5.5)
where σi is the standard deviation of the Gaussian noise for visible unit i. Since learning the variance is
difficult with CD, we use the same strategy as in [269] which normalizes each feature to have zero mean and
unit variance. The variance in Eq. (5.5) is then set to 1, and the resulted learning procedures remain the
same except for that when CD is performed, the reconstructed value of a Gaussian visible unit changes from
sigm(WTh+ b) to (WTh+ b).
5.2.2 Multimodal DBN
Multimodal DBN was originally proposed to learn joint representations from image and text data [5]. In
this study, multimodal DBN is used to learn cross-modality features with raw features extracted based on
PPI networks and GO terms. Fig. 5.2 gives a schematic multimodal DBN for predicting disease genes.
The left and right subnetworks denote two DBNs which model PPI-based features and GO-based features,
respectively. The top network is a DBN that models the joint distribution and a sigmoid activation function
as the output layer for decision making.
According to [270], each DBN in Fig. 5.2 can be regarded as a stack of RBMs and trained in a greedy
layer-wise manner. Starting from the visible layer, every pair of adjacent layers form an RBM, which can
be trained by the approach discussed in Section 5.2.1. In this study, the visible layers in the two sub-models
use Gaussian units, and the corresponding RBMs formed by vp, h
1
p and vg, h
1
g are GBRBM. All the rest
RBMs formed by adjacent hidden layers are BBRBM. Once an RBM is trained, the activation probabilities
of its hidden layer are used as the input data to train the next RBM, and the DBN can be trained in this
layer-wise manner. After training the two sub-DBNs, their output (hidden probabilities of the top layers)
are concatenated, and the resulted representations are used as the input to train the joint DBN.
The whole model is trained in an unsupervised way, and the resulted multimodal DBN can be further
analyzed by many approaches. In this study, we add an output layer with a sigmoid function to predict the
probability of each disease-gene pair being associated using the cross-modality representations learned by
the joint DBN.
5.2.3 Raw feature extraction
The input data of the multimodal DBN is the raw features of disease-gene pairs. These features are ex-
tracted from disease similarity networks and gene similarity networks. Specifically, for each sub-model, a
disease similarity network and a gene similarity network are first constructed. Then, features of diseases
and genes are extracted from their corresponding similarity networks, respectively, by node2vec [62], which
is an algorithm that can learn features for nodes in networks. This algorithm performs random walk on
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a network and captures both local topological information and global structural equivalent properties to
extract features. We choose node2vec because it can generate independent features which are suitable for
the input of the multimodal DBN. In addition, experiments have shown that features obtained by node2vec
are more informative than those of other algorithms in classification task [62].
The following two sections discuss the strategies used to construct similarity networks based on PPI
networks and GO terms.
Similarity networks in PPI-based sub-model
In the PPI-based model, gene-gene interaction network mapped from the PPI network is regarded as the
gene similarity network. This strategy is chosen because interacting proteins may have similar functions
and protein interactions can reflect the functional similarities between the corresponding genes. Meanwhile,
instead of constructing another gene similarity network, the topological structure of the PPI network is also
valuable when extracting features with node2vec.
The disease similarity network NPPId is constructed according to the disease module theory. A disease
module in an interactome is a subgraph consisting of genes associated with the disease [271]. Let M1 =
(V1, E1) denote the disease module of disease d1 in the interactome (gene-gene interaction network). V =
{g11, g12, . . . , g1n1} is a set of disease genes associated with d1, and E1 is a set consisting of their interactions.
M2 = (V2, E2) is another disease module with similar definition. According to [272], the similarity between
two disease modules M1 and M2 can be calculated as follows:
simppi(M1,M2) =
∑
1≤s≤n1 FM2(g1s) +
∑
1≤t≤n2 FM1(g2t)
n1 + n2
(5.6)
where FM (g) = avg(
∑
gi∈M sim(g, gi)) measures the relations between gene g and disease module M , which
is the sum of the transformed similarities between g and the genes in disease module M . Given two genes
g1 and g2 in the PPI network, their transformed similarity is calculated by
sim(g1, g2) =
1, g1 = g2e−sp(g1,g2), otherwise
where sp(g1, g2) is the length of the shortest path between g1 and g2 in the PPI network. The larger the
transformed similarity, the closer the relationship between g1 and g2.
After calculating the similarities between modules M1 and M2, the similarities between diseases d1 and
d2 can be obtained by normalizing the module similarities as follows:
SIMdppi(d1, d2) =
2 ∗ simppi(M1,M2)
simppi(M1,M1) + simppi(M2,M2)
(5.7)
Finally, NPPId is constructed by k nearest neighbors (KNN) algorithm [163]. Specifically, edges are added
to NPPId for each disease and its top-k most similar diseases obtained by Eq. (5.7). These edges are weighted
by the similarity scores of their two connected diseases. In this study, k = 10 is chosen according to our
previous experience [78].
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Similarity networks in GO-based sub-model
Similar to the construction of NPPId , the GO-based similarity networks are also built by KNN algorithm,
except that the similarities between diseases and genes are calculated based on GO instead of PPI network.
GO database provides a set of vocabularies to describe gene products based on their functions in the cell.
Three types of ontologies are defined in GO: biological process, cellular component and molecular function.
All the GO terms exist as directed acyclic graphs (DAGs) where nodes represent terms while edges represent
semantic relations. In this study, we use the approach developed by [130] to measure the semantic similarities
of GO terms and genes.
Let DAGA = (TA, EA) represent GO term A, where TA contains all the successor GO terms of A in the
DAG, and EA contains the semantic relations between A and other terms in TA. Each term t in TA has an
S-value related to A: SA(t) = 1, if t = ASA(t) = max{we ∗ SA(t′)|t′ ∈ children of t}, otherwise (5.8)
where we is the weight of the edge (semantic relations) in the DAG. Two types of semantic relations are used
in the DAG: ’is a’ and ’part of’, and the corresponding we is set as 0.8 and 0.6, respectively, as recommended
in [130].
Given DAGA = (TA, EA) and DAGB = (TB , EB) for two GO terms A and B, the semantic similarity of
these two terms is computed by:
SGO(A,B) =
∑
t∈TA∩TB (SA(t) + SB(t))∑
t∈TA SA(t) +
∑
t∈TB SB(t)
(5.9)
The semantic similarity of one GO term t
′
and a set of GO terms GO = {t1, t2, . . . , tl} is defined as:
simgo(t
′
, GO) = max
1≤i≤l
(SGO(t
′
, ti)) (5.10)
Then, the functional similarity of two genes g1 and g2, annotated by GO term set GO1 = {t11, t12, . . . , t1n1}
and GO2 = {t21, t22, . . . , t2n2}, is calculated by:
SIMggo(g1, g2) =∑
1≤i≤n1 simgo(t1i, GO2) +
∑
1≤j≤n2 simgo(t2j , GO1)
n1 + n2
(5.11)
The similarity of two diseases d1 and d2, associated with two sets of genes V1 = {g11, g12, . . . , g1n1},
V2 = {g21, g22, . . . , g2n2}, is defined as:
SIMdgo(d1, d2) =∑
1≤i≤n1 SG(g1i, DG2) +
∑
1≤j≤n2 SG(g2j , DG1)
n1 + n2
(5.12)
where SG(g
′
, DG) = max1≤i≤l(SIMggo(g
′
, gi)).
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Sub-model input construction
After obtaining the similarity networks, features are extracted by node2vec. Let φpi denote the extracted
feature vector of disease i, and ϕpj denote the extracted feature vector of gene j in the PPI-based model.
Their concatenation, ψpij = (φ
p
i , ϕ
p
j ), is the feature vector of disease-gene pair (i, j) in the PPI-based model,
which is then used as the input of the PPI-based sub-DBN. Similarity, ψgoij is constructed and used as the
input of the GO-based sub-DBN.
5.2.4 Evaluation metrics
The area under Receiver Operating Characteristics (ROC) curve (AUC) is used to evaluate the algorithms.
ROC curve plots the true positive rate [TP/(TP+FN)] versus the false positive rate [FP/(FP+TN)] at
different thresholds, and a larger AUC score represents better overall performance. In this study, a true
positive (TP) is a known disease-gene association (positive sample) predicted as a disease-gene association,
while a false positive (FP) is a non- disease-gene association (negative sample) predicted as a disease-gene
association. A false negative (FN) is a positive sample predicted as negative while a true negative (TN) is
a negative sample predicted as negative.
Considering that negative samples are not included in existing databases, we combine our previous study
in [78] and the idea of reliable negatives in [41] to collect a subset of unknown samples as potential negative
samples (PN). Taking the PPI-based model as an example, let ψpavg denote the average feature vector of all
positive samples. For each unknown sample u, we calculate the Euclidean distance dpu between u and ψ
p
avg.
The average distance is then denoted as dpavg. If d
p
u > d
p
avg, sample u is considered as a reliable negative
sample. With this approach, two sets of reliable negative samples are collected from the PPI-based model
and GO-based model, respectively. disease-gene pairs in the intersection of the two sets are regarded as PN.
In our experiment, 4432 samples (the same as the number of positive samples) are randomly selected from
PN as negative samples and the dataset contains 8864 samples in total. This random selection is performed
three times to generate three sets of data.
The proposed method is evaluated in three steps. First, the whole dataset is randomly split into three
subsets: training set (80%), validation set (10%) and testing set (10%). The optimized hyperparameters are
determined based on the average AUC obtained from 10 randomly split validation sets. The average AUC
obtained from testing sets with the optimized hyperparameters is used to evaluate the overall performance
of the model. Second, dgMDL is compared with two newly developed algorithms: PBCF [257] and Know-
GENE [63] in 5-fold cross-validation. PBCF is an MF-based algorithm and Know-GENE uses the boosted
regression to predict disease-gene associations. Both of them are generic models which use similar types of
data as dgMDL does. For each set of data, the cross-validation is run for five times to remove the influence
of the random splitting. Associations left for testing are not used to calculate disease similarities. Third,
unknown disease-gene pairs are ranked by their probabilities of being associated predicted by dgMDL. The
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top-10 pairs and top-10 unknown lung cancer-related genes are further studied in existing literature to
evaluate the performance of dgMDL in predicting new disease-gene associations.
5.2.5 Hyperparameters
In this study, several hyperparameters affect the accuracy of the prediction. For the multimodal DBN, the
numbers of hidden layers and the number of nodes in each hidden layer determine the architecture of the
model. In our experiments, the model is found to be insensitive to the number of hidden nodes. Thus, we set
the number of hidden nodes in the sub-modal and the joint-model to 256 and 512, respectively. In addition,
since the performance of the model becomes stable when the numbers of hidden layers are larger than 2, we
set the numbers of hidden layers to be 3 in both the sub-DBN and the joint-DBN.
Another three hyperparameters [learning rate (lr), batch size (bs) and number of epochs (ne)] determine
whether the model is well trained. For lr, 0.01 is recommended for training BBRBM in [273]. In our study,
we find that 0.01 is small enough to train the BBRBM. A smaller or adaptive lr barely changes the prediction
accuracy. Thus, lr used for training BBRBM is set to 0.01. Meanwhile, it is recommended that lr used for
training GBRBM should be one or two orders of magnitude smaller than that for BBRBM. Thus, we search
lr of the GBRBM from {0.001, 0.0005, 0.0002, 0.0001}. For bs, a recommended value is usually equal to the
number of the classes, and it would be better if each mini-batch contains at least one sample from each class.
Considering that we only have two classes in this study and using a bs equals to two can hardly guarantee
the recommendation, bs is searched from {2, 4, 8, 10}. For ne, we fix it to 30 because the performance of
dgMDL becomes stable after being trained for 30 epochs. Table S1 in the Supplementary gives the average
AUC obtained from the validation sets with different combinations of lr and bs. The optimized lr for the
GBRBM and bs are 0.0005 and 4, respectively.
For node2vec, the hyperparameters include: dimension of features (d); return parameter (p); in-out
parameter (q); number of walks (r); length of walk (l) and context size (k). The corresponding default
values recommended in [62] are 128, 1, 1, 10, 80 and 10, respectively. Although these hyperparameters
should be changed for networks with different numbers of nodes and edges, searching all of them with
brute force would be time-consuming. In our study, we do test different combinations of d, p, q and l, but
the results are all worse than the ones obtained with the default values. To determine the real optimized
hyperparameters used in node2vec, one might need a large amount of time on the grid search, which is not
the key issue of the deep learning model. Therefore, the default values of node2vec are used in our study.
5.2.6 Data sources
The disease-gene association data are downloaded from the Online Mendelian Inheritance in Man (OMIM)
database [274]. The latest Morbid Map at OMIM contains nearly seventy-five hundred entries sorted alpha-
betically by disease names, thirty-nine hundred genes and more than sixty-one hundred diseases. Each entry
represents an association between a gene and a disease. Different entries are labelled with different tags
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[‘(3)’, ‘[ ]’ and ‘?’] indicating their reliabilities. To get the most reliable entries, in this study three steps are
performed to preprocess the originally downloaded dataset. The first two steps are similar to the approach
used in [154]. From the website of OMIM, diseases with tag ‘(3)’ indicate that the molecular basis of these
diseases is known, which means the associations are reliable. Entries with ‘[ ]’ represent abnormal laboratory
test values while entries with ‘?’ represent provisional disease-gene associations. At the first step, entries
with the tag ‘(3)’ are selected while others are abandoned. At the second step, we classify these disease
entries into distinct diseases by merging disease subtypes based on their given disorder names. For instance,
14 entries of ‘46XX sex reversal’ are merged into disease ‘46XX sex reversal’, and the 9 complementary terms
of ‘Renal cell carcinoma’ are merged into ‘Renal cell carcinoma’. During the classification, string match is
first used to classify adjacent entries, and then the classified results are manually verified. At the third step,
475 diseases are removed because each of them is associated with only one gene which is not associated with
any other diseases. As a result, we obtain the final dataset consisting of 4432 associations between 1154
diseases and 2909 genes. All these disease-gene associations are included in Supplementary Table S2.
The PPI network is obtained from the InWeb InBioMap database (version 2016 09 12) [170], which
consists of more than 600,000 interactions collected from eight databases. The proteins in the network are
mapped to their corresponding genes to form a gene-gene interaction network. In total, there are 17429
genes in the network. GO data are downloaded from the GO database [125, 126]. For genes that have no
ontology information, the values of their features in the GO-based model are all 0.
5.3 Results
5.3.1 Overall performance
Fig. 5.3 shows the average AUC obtained with the hidden representatives learned from different layers
of the model. The raw feature vectors and the activation probabilities learned in each hidden layer are
used to predict disease-gene associations in the testing set. The blue bars and purple bars show the AUC
scores obtained from the PPI-based DBN and GO-based DBN, respectively. AUC scores obtained from the
joint DBN are shown by the red bars. Clearly, the accuracy of the prediction improves when the model
is continuously trained, which shows that the multimodal DBN successfully learns valuable information in
different stages of the training and improves the prediction of disease-gene associations.
5.3.2 Comparison with other algorithms
Fig. 5.4 shows the ROC curves of dgMDL (red), Know-GENE (blue) and PCFM (orange) obtained with 5-
fold cross-validation, respectively. dgMDL achieves an AUC of 0.969 which is the best among three competing
algorithms. The AUC of Know-GENE is 0.941, which is slightly worse than that of dgMDL. PCFM ranks
the 3rd with an AUC of 0.791.
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5.3.3 Prediction of new disease-gene associations
To further evaluate dgMDL, we rank the unknown disease-gene pairs according to their probabilities of being
associated calculated by the model. Since known disease genes are more likely to be associated with other
diseases, we rank the unknown pairs of diseases and existing disease genes in this study. Meanwhile, we also
rank the unknown pairs by Know-GENE and PCFM for comparison. Table 5.1 lists the top-10 ranked pairs
of dgMDL, Know-GENE, and PCFM, respectively. For dgMDL, 8 out of the 10 pairs have been studied in
existing literature. While for Know-GENE and PCFM, only 3 of the 10 pairs have been studied.
In addition to the top-10 prediction, we test the ability of dgMDL in predicting new associated genes for
a specific disease. Table 5.2 lists the top 10 unknown genes associated with lung cancer. 9 out of 10 pairs
have been studied in existing literature. All these results demonstrate that dgMDL is valuable in predicting
new disease-gene associations.
5.4 Conclusion
Integrating multiple types of data with machine learning model is a challenging task, especially for predicting
disease genes where the number of known associations is limited. In this study, we have proposed a method
to predict disease-gene associations with the cross-modality features obtained by multimodal DBN. The deep
learning model learns joint representations from raw features extracted from PPI-based similarity networks
and GO-based similarity networks. Results show that the proposed method is overall more accurate than
the competing algorithms. Further analysis of the top-10 disease-gene pairs and top-10 lung cancer-related
genes also reveal the potential of dgMDL in predicting new disease genes. The current model integrates two
types of data. It is possible that a gene is not included in any of these data, and its associations cannot be
correctly predicted. In the future, more types of data should be integrated by the multimodal DBN, such as
disease-disease associations, protein domain and sequence information, to solve this issue and improve the
prediction accuracy.
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Table 5.1: Top-10 associations predicted by dgMDL, Known-GENE and PCFM
Disease Gene Supporting Evidence
dgMDL
Deafness PIK3CD [275]
Deafness PIK3CA
Deafness PIK3R1 [276]
Diabetes AR [277]
Deafness PTPN11 [278]
Diabetes SMAD4 [279]
Cataract AR
Diabetes GATA3 [280]
Mental retardation SMAD4 [281]
Deafness STAT3 [282]
Know-GENE
Acne inversa familial NLRP12
Basal cell nevus syndrome HGF
Bladder cancer somatic PIK3CA [283]
Bladder cancer somatic NRAS
Cardiofaciocutaneous syndrome EGFR
Complement factor I deficiency C3 [284]
LADD syndrome PIK3CA
Meckel syndrome B9D1 [285]
Nevus epidermal somatic ERBB2
Nevus epidermal somatic RET
PCFM
Mental retardation CLCN7
Mental retardation PDE3A
Mental retardation RBM12
Mental retardation BPTF [286]
Mental retardation TAP1
Mental retardation LAMTOR2 [287]
Mental retardation DYSF
Mental retardation TPRKB
Mental retardation HERC1 [288]
Mental retardation RORC
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Table 5.2: Top-10 susceptible lung cancer-associated genes
Gene Supporting Evidence
PTPN11 [289]
PIK3R1 [290]
HRAS [291]
GATA3 [292]
PIK3CD
JAK2 [293]
STAT3 [294]
C5 [295]
SIK1 [296]
PPM1D [297]
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6deepDriver: predicting cancer driver genes based on somatic muta-
tions using deep convolutional neural networks
Prepared as: Ping Luo, Yulian Ding, Xiujuan Lei, and Fang-Xiang Wu. deepdriver: Predicting cancer
driver genes based on somatic mutations using deep convolutional neural networks. Frontiers in Genetics,
10:13, 2019. PL, YD, XL and FXW discussed about the methods. PL implemented the algorithm, designed
and performed the experiments. FXW supervised this study. PL and FXW wrote the manuscript. All
authors read, revised and approved the final version of the manuscript.
The previous chapter use multimodal DBN to fuse different types of data, the model would become
complex when fusing several types of data. A convolutional layer and pooling layer should help to reduce the
dimension of the learned representations. Thus, in this chapter, the CNN model is applied to fuse different
types of data and predict disease genes. This chapter fulfills Objective 5 of this thesis.
Abstract
With the advances in high-throughput technologies, millions of somatic mutations have been reported in the
past decade. Identifying driver genes with oncogenic mutations from these data is a critical and challenging
problem. Many computational methods have been proposed to predict driver genes. Among them, ma-
chine learning-based methods usually train a classifier with representations that concatenate various types
of features extracted from different kinds of data. Although successful, simply concatenating different types
of features may not be the best way to fuse these data. We notice that a few types of data characterize
the similarities of genes, to better integrate them with other data and improve the accuracy of driver gene
prediction, in this study, a deep learning-based method (deepDriver) is proposed by performing convolution
on mutation-based features of genes and their neighbors in the similarity networks. The method allows the
convolutional neural network to learn information within mutation data and similarity networks simultane-
ously, which enhances the prediction of driver genes. deepDriver achieves AUC scores of 0.984 and 0.976 on
breast cancer and colorectal cancer, which are superior to the competing algorithms. Further evaluations of
the top 10 predictions also demonstrate that deepDriver is valuable for predicting new driver genes.
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6.1 Introduction
Cancer is driven by various types of mutations, such as single nucleotide variants (SNVs), insertions or
deletions (Indels) and structural variants. Identifying driver genes whose mutations cause cancer could help
us decipher the mechanism of cancer, which is beneficial to the development of novel drugs and therapies.
With the advances in next-generation sequencing technologies, massive amounts of cancer genomic data
have been published, which elevate the identification of driver genes. Currently, many computational methods
have been proposed, and they can be divided into several types. A typical kind of method is those based
on the mutation frequency. These methods find “significantly mutated genes” (SMG) whose mutation rates
are significantly higher than the background mutation rate and judge them as driver genes. For instance,
OncodriveCLUST finds positions with mutation rates higher than the background mutation rate and predicts
driver genes from clusters generated based on these seed positions [298]. MutsigCV identifies SMGs by
building a patient-specific background mutation model with gene expression data and DNA replication time
data [299]. However, due to the heterogeneity of tumors, constructing a reliable background mutation model
is difficult [13], which limits the performance of frequency-based methods. Another type of methods predicts
driver genes by network analysis. For example, DawnRank predicts driver genes by ranking the genes in
a gene interaction network (GIN) with PageRank algorithm [300]. SCS uses network control strategy to
find driver mutations that can drive the regulation network from the normal state to disease states [301].
Considering that GINs are downloaded from online databases, such as BioGrid [302] and HPRD [89], which
contain many false positives, network-based methods need more accurate GIN to improve their prediction
accuracy.
As the increasing number of experimentally validated driver genes, researchers start to use machine
learning algorithms to predict new driver genes. These methods usually train a classifier with features
characterizing the functional impact of mutations. For instance, CHASM trains a random forest classifier
with 86 predictive features [303]. CanDrA trains an SVM with 95 features obtained from ten functional
impact-based algorithms, such as SIFT [304] and CHASM. Since the number of driver genes is much smaller
than that of passenger genes, selecting gold-standard driver genes (positive data) and a set of high-quality
nonfunctional passenger genes (negative data) is difficult for machine learning-based methods. However, with
reasonable downsampling, these methods can also achieve better performance than other types of algorithms.
Tokheim et al. propose a random forest algorithm (known as 20/20+) and compare it with seven classical
driver gene prediction algorithms (ActiveDriver [305], MuSiC [306], MutsigCV [299], OncodriveCLUST [298],
OncodriveFM [307], OncodriveFML [308] and TUSON [256]) in [144]. Results show that 20/20+ performs
best among the eight algorithms, which demonstrate that machine learning models are able to predict driver
genes given the limited known driver-disease associations.
At present, most machine learning-based methods use random forest and SVM as the classifier. To
improve the prediction accuracy, various kinds of features extracted from different types of data are used
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to train the classifier. Despite the increase of the dimensionality, simply concatenating all these features
may not be the best approach to integrate different types of data. Considering that several types of data
can be used to characterize the similarities of genes, if we construct similarity networks with these data and
combine them with other predictive features, the prediction accuracy of the algorithms should be improved
compared to that obtained from a simple feature concatenation. Thus, in this study, a deep learning-based
method is proposed to predict driver genes by combining similarity networks with features that characterize
the functional impact of mutations (deepDriver). Specifically, candidate driver genes are predicted by a
convolutional neural network (CNN) trained with mutation-based feature matrix constructed based on the
topological structure of a similarity network. The algorithm leverages the similarity of gene expression
patterns and the functional impact of mutations simultaneously, which can better fuse these two types of
data and improve the prediction accuracy. To our knowledge, this is the first time that CNN is combined
with similarity network to predict driver genes.
In the rest of the paper, Section 6.2 describes the methods and the materials used in the study. Section
6.3 analyzes the results of the evaluation. Section 6.4 draws some conclusions.
6.2 Material and methods
6.2.1 General model
CNN is successful in many areas, such as image classification and speech recognition. The key component
of a CNN is the convolutional (CONV) layer, which helps the model to learn local and global structures
from the input data. In an image classification problem, these structures include edges, curves, corners, etc.
While in a driver gene prediction problem, traditional input data contain distinct features that characterize
different properties of genes, which cannot be directly applied to CNN.
We notice that pixels in a small region share the same filters because they have similar grayscale. In
a gene similarity network (GSN), genes and their neighbors also have similar properties. If we reconstruct
the traditional input data with GSN so that features of similar genes are close to each other, CNN can then
be applied to these reconstructed data. Instead of edges and curves learned from the images, topological
structures of the similarity networks are learned by CNN with this strategy. In addition, the strategy allows
CNN to learn the similarities of genes and the properties of the original input data simultaneously, which
can improve the accuracy of driver gene prediction.
Fig. 6.1 depicts a schematic example of a 1-dimensional CNN, which is used in our study. The model
consists of five kinds of layers: Input layer, CONV layers, pooling layers, Fully-Connected (FC) layers, and
Output layer. Given a feature matrix φi ∈ R2k×nf constructed by the feature vectors of gi and its k neighbors
where nf is the dimension of the feature vectors of gi, the output of a CONV layer corresponds to the input
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φi and the filter wj is calculated as follows
A(i, j) = f(wjφi + bj) (6.1)
where bj denotes the bias corresponds to wj , f is an activation function which is ReLU in this study. wjφi
is still the dot product of wj and φi except that the calculation is restricted to be local spatially. Each
CONV layer is followed by a pooling layer, and the CONV-POOL pattern is repeated for several times. The
final structure of the model used for driver gene prediction is determined by grid search, and the results are
discussed in Section 6.3.2. The construction of φi is discussed in the next section.
6.2.2 Network-based convolution
The convolution is performed by combining mutation-based features with gene similarity networks. Many
approaches can be used to calculate the similarities of genes. In this study, to characterize the relationships
between genes in the disease states, Pearson correlation coefficient (PCC) defined by the following equation
is used to calculate the similarities.
r(gi, gj) =
∑v
q=1(eiq − e¯i)(ejq − e¯j)√∑v
q=1(eiq − e¯i)2
√∑v
q=1(ejq − e¯j)2
(6.2)
where ei = (ei1, ei2, . . . , eiv) denotes the expression values of gi in v tumor samples, and e¯i is the mean of
ei. An undirected network N is constructed by k-nearest neighbors (kNN) algorithm [163] in which every
gene is connected to genes that have the k largest PCC scores with itself.
After obtaining N , the construction of φi used in the convolution is depicted by Fig. 6.2. Assuming we
have obtained a feature vector xi for each gene gi, and gs1, gs2, . . . , gsk are the k nearest neighbors of gi in
N , where pcc(gi, gs1) > pcc(gi, gs2) > · · · > pcc(gi, gsk). Feature matrix φi ∈ R2k×nf is built as depicted by
the figure. In φi, features of similar genes are close to each other so that they can share the same filters in
the CONV layer.
6.2.3 Mutation-based features
For each gene of a specific disease, twelve features are extracted from the mutation datasets. Table 6.1
lists the names and descriptions of these features. Among them, the first eight ones measure the fraction
of a specific type of mutation among all the mutations. The tenth and eleventh feature measure the rate of
missense mutations and non-silent mutations to silent mutations, respectively. The last two features measure
the positional clustering of different types of mutations and are calculated as follows
Ei =
−∑i pj log2 pj
log2m
(6.3)
For the normalized missense entropy, m is the total number of missense mutations of gi, and pj = κj/m
where κj is the number of missense mutations in the j-th codon. For the normalized mutation entropy,
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m is the total number of all types of mutations of gi. Different mutations are binned together based on
their types, except for that missense mutations are binned based on their codon positions, different silent
mutations are divided into their own bins. Inactivating mutations (nonsense, translation start site, nonstop,
splice site) are grouped into a single bin.
These twelve features have been used in many machining learning-based methods [309, 144]. To demon-
strate the superiority of our model, we did not use any other features proposed by specific methods. In
addition, during the implementation of the competing methods (SVM, 20/20+), only these twelve features
are used to train their models.
6.2.4 Data sources
In this study, deepDriver was evaluated on three types of cancer: breast invasive carcinoma (BRCA), colon
adenocarcinoma (COAD) and lung adenocarcinoma (LUAD). The mutation data and gene expression data of
these three diseases were downloaded from the NCI Genomic Data Commons (GDC) [104]. For the mutation
data, quality control was applied by filtering out hypermutated samples (> 1, 000 intragenic somatic variants)
[309]. In total, 228,046, 168,746 and 287,667 somatic variants were obtained for BRCA, COAD, and LUAD,
respectively. For gene expression, datasets of 1,102 BRCA, 478 COAD and 551 LUAD primary tumor
samples measured by RNA-Seq were downloaded. We chose the data normalized by FPKM and converted
the values to TPM by the method proposed in [224]. Three steps were then performed to remove the genes
that are barely expressed in tumor samples. First, TPM values less than 1 were considered unreliable and
replaced by 0. Second, log2(TPM + 1) was applied to all TPM values. Third, genes expressed in less than
10% of all tumor samples were removed.
Gene ids were standardized to the gene names provided by HUGO Gene Nomenclature Committee
(downloaded Aug 1, 2018) [310]. Only genes that have both mutation and expression data are kept. Finally,
13,777 genes for BRCA, 11,282 genes for COAD and 13,731 genes for LUAD passed the quality control.
The driver genes were collected from two sources—the Cancer Gene Census category (CGC) [87] and the
genes published in [311]. Genes in CGC were divided into two tiers, and we used genes in Tier 1 as driver
genes because strong evidence has proved their oncogenic role in cancer genesis. It is of note that both
oncogene and tumor suppressor gene (TSG) are regarded as driver gene in this study. In total, 37 driver
genes for BRCA, 42 driver genes for COAD and 12 driver genes for LUAD were collected from CGC. The
Bailey et al.´s dataset [311] contains 299 driver genes associated with 33 types of cancer. In total, 29 driver
genes for BRCA, 20 driver genes for COAD and 20 driver genes for LUAD were collected. These driver genes
as well as a few sets of non-disease genes were regarded as “ground truth” in the evaluation. Details of the
non-disease genes are discussed in next section.
To validate the performance of the algorithm, the structure of the model was first determined by the
grid search using the driver genes of BRCA and COAD collected from CGC. Then, the optimal model was
directly applied to LUAD without fine-tuning the hyperparameters. Similarly, when the model was trained
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with the driver genes published in [311], the optimal hyperparameters were used without fine-tuning.
6.2.5 Evaluation metrics
The algorithm was evaluated in two steps. In the first step, deepDriver was compared with 20/20+ and
SVM in terms of the AUC (area under the receiver operating characteristic (ROC) curve) scores obtained
from 10-fold cross-validation. ROC curve plots the false positive rate (FPR) against the true positive rate
(TPR) at different thresholds. FPR and TPR are defined as follows
FPR =
FP
FP + TN
TPR =
TP
TP + FN
(6.4)
where TP , FP , TN , and FN are the numbers of true positives, false positives, true negatives, and false
negatives, respectively. In this study, a true positive is a driver gene predicted as a driver gene, a false
positive is a passenger gene predicted as driver gene, a true negative is a passenger gene predicted as a
passenger gene, and a false negative is a driver gene predicted as a passenger gene. The larger the AUC is,
the better the performance of the algorithm is.
Since the number of passenger genes is much larger than that of the driver genes, a method is needed to
solve the imbalanced issue. Currently, two types of methods can be used to solve the imbalanced problem:
data level methods and classifier level methods [312]. In this study, a data level method, downsampling,
was used to reduce the size of the passenger genes. Specifically, a subset of passenger genes was randomly
selected from all the passengers so that the numbers of positive samples (driver genes) and negative samples
(passenger genes) are equal. This approach was run for five times which generated five sets of data. During
the cross-validation, for each set of data, all the positive and negative samples were randomly split into ten
groups, and the CNN model was validated for ten rounds. In each round, one group of samples were used
as the testing data while the rest nine groups of samples were used as the training data.
Additionally, since passenger genes are barely reported in existing literature, in this study, genes that
have not been reported as cancer driver genes (unknown genes) were regarded as passenger genes. This
strategy was used because of the following two reasons. First, the numbers of the selected passenger genes
and the undiscovered driver genes are both much less than that of the unknown genes. Potential driver genes
only have a small change to be selected as passenger genes [256]. Second, the final results were obtained by
taking the average predictions of the five sets of data. This bagging strategy would improve the stability
and accuracy of the results and reduce the impact of a potential driver gene selected as a passenger gene.
Finally, the 10-fold cross-validation was run for five times for each dataset to reduce the influence of random
shuffling, and the average AUC score was used to evaluate the performance of the algorithms.
In the second step, all the unknown genes were ranked by their probabilities of being driver genes, and
the top 10 predictions were searched from the existing literature to check whether our predictions are in
concert with existing studies. We also ranked the unknown genes by SVM, 20/20+ and OncodriveCLUST
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and compared their results with those of deepDriver in terms of the number of genes having been analyzed
in existing literature.
6.2.6 Implementation
The algorithm was implemented using Keras [313] with TensorFlow [314] as the backend engine. We have
tested the program on both CPU and GPU versions of TensorFlow and the model can be efficiently trained
with or without the help of GPU. A reference implementation is available at cnnhttps://github.com/
luoping1004/deepDriver.
6.3 Results
6.3.1 Hyperparameters
In this study, the architecture of CNN is determined by the following hyperparameters.
1. The number of the CONV layers (ncl)
2. The number of the FC layers (nfl)
3. The number of the nodes in the CONV layers (ncn)
4. The number of the nodes in the FC layers (nfn)
These hyperparameters were determined by grid search, with ncl searched from {1,2,3,4}, nfl searched from
{1,2,3}, ncn searched from {12,24,48} and nfn searched from {24,48,96}. The optimal values of ncl, nfl, ncn
and nfn are 2, 1, 24 and 48, respectively. In addition, zero padding was used in the CONV layers except the
first one. The size of the filters, the window size of the pooling layers and the stride sizes used in the CONV
layers and the pooling layers were all empirically set to 2.
The number of neighbors used by kNN algorithms was also determined by grid search. We searched k
from {3,5,7,9,11,13,15}, and finally, k = 9 and k = 7 were chosen for BRCA and COAD, respectively. In
fact, the AUC scores were all above 0.950 when 7 ≤ k ≤ 15. Based on our previous study, k = 7 is enough
to generate high-quality similarity networks [78]. Thus, k = 7 was used when the dataset of LUAD was
analyzed by our deepDriver. Meanwhile, for other types of cancer not discussed in this study, k = 7 is also
recommended when the similarity network is constructed.
For 20/20+, a random forest of 200 trees was used based on the suggestions of [144]. For SVM, the
model was implemented with a linear kernel and RBF kernel. The penalty parameter C was searched from
{0.1, 0.01, 0.001, 1, 10, 100, 1000}, and γ was searched from {1/12, 0.001, 0.0001, 0.00001}. Finally, for
BRCA and COAD, SVM performed the best with an RBF kernel, when C = 1, γ = 0.0001; for LUAD, SVM
performed the best with an RBF kernel, when C = 1000, γ = 0.00001.
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6.3.2 Cross-validation
Fig. 6.3, Fig. 6.4 and Fig. 6.5 show the results of the ROC curves and the corresponding AUC scores
of deepDriver, 20/20+ and SVM on BRCA, COAD and LUAD, respectively. According to the figures,
deepDriver achieved AUC scores of 0.984, 0.976 and 0.998 on BRCA, COAD and LUAD, respectively, which
were at least 15.1% higher than those of the two competing algorithms, especially for COAD and LUAD
where the AUC scores of the competing algorithms were less than 0.750.
To further demonstrate that the model was not overfitted, the learning curves were plotted using the
datasets of the three types of cancer. For each type of cancer, 80% of the total samples were used as training
data while the rest 20% samples were left to test the performance of the model. Fig. 6.6, Fig. 6.7 and Fig.
6.8 show the results of the learning curves. The AUC scores obtained from the testing set improved with
the increase of the number of the training samples, which demonstrates that the model is not overfitted. In
the meantime, the AUC scores obtained with a small amount of samples also demonstrate that the model is
able to produce meaningful results even if the number of the known driver genes is less than 10.
In addition to the driver genes collected from CGC, our deepDriver was also validated using the driver
genes published in [311]. As discussed in Section 6.2.4, the optimal hyperparameters obtained from the first
set of drivers were directly used to evaluate the model. Fig. 6.9 depicts the resulted ROC curves. Our
deepDriver obtained AUC scores of 0.985, 0.941 and 0.970 on BRCA, COAD, and LUAD, respectively.
6.3.3 De novo study
To further evaluate the performance of deepDriver, the unknown genes were ranked by their probabilities of
being driver genes predicted by the model. Similar to the cross-validation, 5 sets of data were used to train
the model and the unknown genes were ranked by the average probabilities. Meanwhile, we also ranked the
unknown genes using the three competing algorithms and compared their results with those of deepDriver
in terms of the number of genes that have been studied as drivers in existing literature.
Table 6.2 shows the top 10 predicted driver genes of deepDriver. 6 out of the 10 genes have been studied
in existing literature or databases as potential driver genes of BRCA. The ninth gene ’DST’ was found to
have the potential to drive ductal carcinoma in situ to breast cancer [315]. 5 out of the 10 genes have been
studied as driver genes of COAD in the existing literature. Meanwhile, among the rest 5 genes, ’AMER1’
and ’ADAMTSL3’ were found to be frequently mutated in COAD [316, 317]. ’LAMA3’ were predicted as
biomarkers which could be used to diagnose COAD in the early stage [318]. ’KMT2A’ belongs to the KMT2
family which is related to COAD [319]. 4 out of 10 genes have been studied as driver genes of LUAD. The
tenth gene ’HERC2P3’ contains a microsatellite locus that can precisely discriminate LUAD samples and
non-tumor samples [320]. As for three competing algorithms, Table 6.3, 6.4 and 6.5 show their prediction
results. In summary, deepDriver performed better than the three competing algorithms in predicting new
cancer drivers. Its prediction results were in concert with existing studies which further reveal the value of
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deepDriver in predicting cancer driver genes.
6.4 Conclusion
In this study, we proposed an algorithm to predict cancer driver genes with CNN. The method combined
CNN with similarity networks so that the functional impact of mutations and similarities of gene expression
can be learned simultaneously, which improve the accuracy of driver gene prediction. Experiments performed
on BRCA, COAD and LUAD then showed that deepDriver was superior to the competing algorithms in
terms of both cross-validation and de novo prediction.
In the future, similarity networks calculated by different strategies and predictive features extracted by
other algorithms can both be used to improve the prediction accuracy. Meanwhile, the algorithm can be
applied to the pancancer dataset to predict generic cancer driver genes. Since the total number of cancer
driver genes is much higher than that of a specific type of cancer, candidate driver genes can also be further
classified into TSG and oncogene on the pancancer dataset.
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Table 6.1: 12 features extracted from mutation data.
No. Name Description
1 Silent fraction Fraction of silent mutations
2 Nonsense fraction Fraction of nonsense mutations
3 Splice site fraction Fraction of splice site mutations
4 Missense fraction Fraction of missense mutations
5 Recurrent missense fraction Fraction of recurrent missense mutations
6 Frameshift indel fraction Fraction of frameshift indel mutations
7 Inframe indel fraction Fraction of Inframe indel mutations
8 Lost start and stop fraction Fraction of Lost start and stop mutations
9 Missense to silent Ratio of missense to silent mutations
10 Non-silent to silent Ratio of non-silent to silent mutations
11 Normalized missense position entropy See Section 6.2.3
12 Normalized mutation entropy See Section 6.2.3
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Table 6.2: Top 10 predictions of deepDriver
Gene Names Reference
BRCA
PTEN [321]
HCFC1 [322, 323]
UTRN [324]
ZNF517
STAG2 [322, 323]
ZFP36L1 [325]
ZNF91
VPS13C
DST
FBXW7 [326]
COAD
AMER1
SOX9 [327]
NRAS [328]
MTOR [329]
ATM [330]
ADAMTSL3
ELMO1 [331]
TG
LAMA3
KMT2A
LUAD
XIST [332]
MALAT1 [333]
STK11 [334]
USH1C
HSP90AB2P
BNIP3P1
EEF1A1P9
UBE2MP1
SMAD4 [335]
HERC2P3
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Table 6.3: Top 10 predictions of 20/20+
Gene Names Reference
BRCA
KMT2C [336]
PTEN [321]
ANKRD12
NF1 [337]
ANKHD1-EIF4EBP3
ARID4B
MCM7
MYO6
MLLT4 [323]
CEP128
COAD
ATM [330]
SOX9 [327]
LAMA3
ADAMTSL3
ELMO1 [331]
OLFM1
BRINP1
ACVR1B
CNOT1
PCDH7
LUAD
LRRIQ1
HECTD4
EPB41L3 [338]
NF1 [339]
CEP350
PRKDC
APC
MYH9
POSTN
FN1
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Table 6.4: Top 10 predictions of SVM
Gene Names Reference
BRCA
VPS13C
UTRN [324]
HCFC1 [322, 323]
MLLT4 [323]
ZNF91
STAG2 [322, 323]
FBXW7 [326]
MALAT1
NRK
BAZ2B
COAD
ATM [330]
NRAS [328]
MTOR [329]
SOX9 [327]
ADAMTSL3
ELMO1 [331]
AMER1
KMT2B
FBN2
KMT2A
LUAD
XIST [332]
MALAT1 [333]
USH1C
SNRPN
STK11 [334]
SMAD4 [335]
POLA1
MAGEE1
BRAF
CTNNB1
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Table 6.5: Top 10 predictions of OncodriveCLUST
Gene Names Reference
BRCA
ACTN4 [340]
AFF2
ATP2B3
AVPR1B
CASR
CMYA5
DIS3L
EPB41L2
FBXW8
KCND3
COAD
AKAP12 [341]
C3orf20
COL1A2 [342]
DOK1 [343]
FNDC1
MSRB3
NCOA2 [344]
NPHS1
NRAP
PCDHB13
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CONV
Input
CONV
Pooling
Pooling
FC
Output
..
.
Figure 6.1: Schematic 1-D CNN. In this study, each CONV layer is followed by a pooling layer and
the CONV-POOL pattern is repeated for several times. The final structure of the model is determined
by grid search.
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Figure 6.2: Construction of φi. Given the feature vectors of gi and its k nearest neighbors
gs1, gs2, . . . , gsk, a feature matrix φi is constructed by arranging the 2k vectors into a 2k×nf matrix,
which is then used in the convolution.
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Figure 6.3: ROC curves of the three algorithms obtained on the dataset of BRCA. The red, green
and magenta lines depict the ROC curves of deepDriver, 20/20+ and SVM, respectively. The AUC
value of deepDriver is 0.984, which is at least 15.1% higher than that of the other two algorithms.
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Figure 6.4: ROC curves of the three algorithms obtained on the dataset of COAD. The red, green
and magenta lines depict the ROC curves of deepDriver, 20/20+ and SVM, respectively. The AUC
value of deepDriver is 0.976, which is at least 25.5% higher than that of the other two algorithms.
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Figure 6.5: ROC curves of the three algorithms obtained on the dataset of LUAD. The red, green
and magenta lines depict the ROC curves of deepDriver, 20/20+ and SVM, respectively. The AUC
value of deepDriver is 0.998, which is at least 24.9% higher than that of the other two algorithms.
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Figure 6.6: Learning curve for BRCA.
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Figure 6.7: Learning curve for COAD.
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Figure 6.8: Learning curve for LUAD.
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Figure 6.9: ROC curves of deepDriver obtained from the second sets of driver genes.
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7Identifying disease-gene associations with graph-regularized manifold
learning
Prepared as: Ping Luo, Qianghua Xiao, Pi-Jing Wei, Bo Liao, and Fang-Xiang Wu. Identifying disease-
gene associations with graph-regularized manifold learning. Frontiers in Genetics, 10:270, 2019. PL, QX,
PJW, BL and FXW discussed about the methods. PL implemented the algorithm, designed and performed
the experiments. FXW supervised this study. PL and FXW wrote the manuscript. All authors read, revised
and approved the final version of the manuscript.
In previous chapters, a few supervised models are used to predict disease genes. If the models have to be
trained separately for different diseases, the corresponding methods cannot be applied for diseases with only
a few or no known associated genes, since the number of the instances is not enough to train the models.
To solve this issue, we can extract features for both diseases and genes and predict disease-gene associations
instead of associated genes for a specific disease. The number of the positive instances is then equals to
the number of all known disease-gene associations, which is large enough to train the model. For instance,
algorithms proposed in Chapter 5 has used this strategy. Additionally, we can also use NMF-based methods
to solve this issue. These methods define disease-gene prediction as a matrix completion problem. Each
entry in the association matrix is regarded as the probability of a disease-gene pair being associated.
In this chapter, we also propose an NMF-based method. However, unlike existing methods which use
matrix completion to solve the problem, we map the diseases and genes onto a lower dimensional manifold
and use their geodesic distance to determine whether they are associated. Our assumption is that the
distance among a disease and its associated genes should be smaller than that among the disease and other
genes. This chapter fulfills Objective 6 of this thesis.
Abstract
Complex diseases are known to be associated with disease genes. Uncovering disease-gene associations is
critical for diagnosis, treatment, and prevention of diseases. Computational algorithms which effectively
predict candidate disease-gene associations prior to experimental proof can greatly reduce the associated
cost and time. Most existing methods are disease-specific which can only predict genes associated with a
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specific disease at a time. Similarities among diseases are not used during the prediction. Meanwhile, most
methods predict new disease genes based on known associations, making them unable to predict disease genes
for diseases without known associated genes. In this study, a manifold learning-based method is proposed
for predicting disease-gene associations by assuming that the geodesic distance between any disease and its
associated genes should be shorter than that of other non-associated disease-gene pairs. The model maps
the diseases and genes into a lower dimensional manifold based on the known disease-gene associations,
disease similarity and gene similarity to predict new associations in terms of the geodesic distance between
disease-gene pairs. In the 3-fold cross-validation experiments, our method achieves scores of 0.882 and 0.854
in terms of the area under of the receiver operating characteristic (ROC) curve (AUC) for diseases with more
than one known associated genes and diseases with only one known associated gene, respectively. Further
de novo studies on Lung Cancer and Bladder Cancer also show that our model is capable of identifying new
disease-gene associations.
7.1 Introduction
Complex diseases are caused by a group of genes known as disease genes. Identifying disease-gene associations
is of critical importance since it helps us unravel the mechanisms of diseases, which has many applications
such as diagnosis, treatment and prevention of disease. With the advances in high-throughput experimental
techniques, a large amount of data that indicate associations between diseases and their associated genes have
been generated, which could accelerate the identification of disease-associated genes. However, it is expensive
and time-consuming to experimentally prove an association between a gene and a disease. Computational
methods that translate the experimental data into legible disease-gene associations are necessary for in-depth
experimental validation.
Currently, many algorithms have been developed to predict disease-gene associations, and they can be
briefly divided into two categories: the machine learning-based methods and the network-based methods. The
typical machine learning-based methods extract gene-related features and train models that can discriminate
disease genes and passenger genes [3, 78, 41, 220, 345]. Since the features are extracted for genes, these
algorithms are usually single-task algorithms which once can only predict disease genes for a specific disease.
Thus, for diseases that have a few or no known associated genes, the number of the genes would be too small
to train the model. In the meantime, the relationships among diseases are usually not used in the prediction
since only one disease is considered at a time. Matrix completion methods, as a type of machine learning
methods, can solve the above two issues by jointly predicting disease-gene associations and leveraging the
similarities among diseases during the calculation [6, 7]. However, matrix completion methods generally do
not have the global optimal solutions and could take a very long time to converge to even a local optimal
solution. Network-based methods are based on the assumption that genes close related in the network are
associated with the same diseases. Centrality indices, random walk and network energy are used in many
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methods to predict disease-gene associations [18, 22, 47, 44]. Although most network-based methods are not
affected by the above two issues, their performance is strongly affected by the quality of networks, and they
usually perform worse than machine learning-based methods on diseases with many known associated genes
[117, 118].
In this study, we propose a manifold learning-based method (dgManifold) to predict disease-gene associ-
ations. In our dgManifold, genes and diseases are regarded as points in the same high-dimensional Euclidean
space. Our assumption is that diseases and their associated genes should be consistent in some lower di-
mensional manifold, and the geodesic distance between a disease and its associated genes should be shorter
than that of other non-associated disease-gene pairs. Although the Euclidean distance between diseases and
genes in the high-dimensional space may not reflect their true geodesic distance, we can map the diseases
and genes into a low-dimensional manifold based on the experimentally verified disease-gene associations
[346, 347]. Then, the true geodesic distance between all the disease-gene pairs can be calculated. In the
meantime, the mapping process is regularized by two affinity graphs, disease similarity network and gene
similarity network, so that the learned representations with the similarity information can further increase
the prediction accuracy. Additionally, since our dgManifold is a supervised method, and it is difficult (if
possible) to learn valuable representations for diseases that only have a few or no known associated genes. A
prior information vector calculated with the disease similarities and known disease-gene associations should
be combined with the original association data to solve this issue. Similar strategies have been applied to
calculate the initial probabilities used in the random walk, which have improved the accuracy of predicting
miRNA-disease associations. [348, 349, 350].
In the rest of the manuscript, Sections 7.2 describes our algorithm as well as the data sources and
evaluation metrics used in the study. Section 7.3 discusses the evaluation results. Section 7.4 draws some
conclusions.
7.2 Methods and material
7.2.1 General model
Given n diseases and m genes, the associations among them can be represented by a matrix A ∈ Rn×m
in which aij = 1 if disease i is associated with gene j, and otherwise aij = 0. Intuitively, each disease
can be represented by a binary m-dimensional row vector while each gene can be represented by a binary
n-dimensional column vector. However, in these high-dimensional spaces, it is hard to calculate the actual
distance between a disease and a gene.
If we map the diseases and genes into the same manifold with a lower dimensionality and assume that
the distance between a disease and its associated genes should be as short as possible on this manifold,
predicting disease-gene associations can be solved by computing this mapping based on known disease-gene
associations, which can be mathematically formulated as: finding k-dimensional representatives of diseases
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r1, . . . , rn and k-dimensional representatives of genes q1, . . . ,qm such that the following objective function
is minimized
Ok =
n∑
i=1
m∑
j=1
aij‖ri − qj‖2. (7.1)
However, without any constraints, the objective function (7.1) is not well defined. To illustrate this, if
k-dimensional vectors r+i and q
+
j for i = 1, . . . , n and j = 1, . . . ,m minimize the objective function (7.1),
then r+i and q
+
j can further minimize the objective function when 0 ≤  < 1. Especially, when  = 0, any
k-dimensional vectors r+i and q
+
j can minimize the objective function. Therefore, to make the optimization
problem well defined, the following constraints are added
n∑
i=1
rir
T
i = Ik and
m∑
j=1
qjq
T
j = Ik. (7.2)
where Ik is the k × k identity matrix. As a results, the learned representations are unique with these
constraints.
To insure that the mapped representations of diseases and genes are in concert with their intrinsic
properties, two affinity graphs, disease similarity network and gene similarity network are used to regularize
the objective function (7.1), and the new objective function is as follows
Ok =
m∑
j=1
n∑
i=1
aij‖ri − qj‖2 +
α
2
n∑
i=1
n∑
j=1
sdij‖ri − rj‖2 +
β
2
m∑
i=1
m∑
j=1
sgij‖qi − qj‖2 (7.3)
where Sd and Sg are the adjacency matrices of the disease similarity network and the gene similarity network,
respectively. α and β are the regularization coefficients.
Note that
Ok =
n∑
i=1
(
m∑
j=1
aij)r
T
i ri +
m∑
j=1
(
n∑
i=1
aij)q
T
j qj − 2
n∑
i=1
m∑
j=1
aijr
T
i qj
+α
n∑
i=1
(
n∑
j=1
sdij)r
T
i ri − α
n∑
i=1
n∑
j=1
sdijr
T
i rj
+β
m∑
i=1
(
m∑
j=1
sgij)q
T
i qi − β
m∑
i=1
m∑
j=1
sgijq
T
i qj
=
n∑
i=1
Arir
T
i ri +
m∑
j=1
Acjq
T
j qj − 2
n∑
i=1
m∑
j=1
aijr
T
i qj
+α
n∑
i=1
Sdi r
T
i ri − α
n∑
i=1
n∑
j=1
sdijr
T
i rj
+β
m∑
j=1
Sgj q
T
j qj − β
m∑
j=1
m∑
i=1
sgijq
T
i qj
=
n∑
i=1
(Ari + αS
d
i )r
T
i ri +
m∑
j=1
(Acj + βS
d
j )q
T
j qj
−2
n∑
i=1
m∑
j=1
aijr
T
i qj − α
n∑
i=1
n∑
j=1
sdijr
T
i rj − β
m∑
j=1
m∑
i=1
sgijq
T
i qj
(7.4)
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where Sdi =
∑n
j=1 s
d
ij , S
g
i =
∑m
j=1 s
g
ij , Ari =
∑m
j=1 aij , Acj =
∑n
i=1 aij . Let
L11 = diag[Ar1 + αS
d
1 , Ar2 + αS
d
2 , . . . , Arn + αS
d
n]− αSd,
L22 = diag[Ac1 + βS
g
1 , Ac2 + βS
g
2 , . . . , Acm + βS
g
m]− βSg,
(7.5)
the objective function (7.3) can be simplified as
Ok =
n∑
i=1
n∑
j=1
L11rTi rj +
m∑
i=1
m∑
j=1
L22qTi qj − 2
n∑
i=1
m∑
j=1
aijr
T
i qj (7.6)
Furthermore, let
ri =

xi1
xi2
...
xik
 , qj =

yj1
yj2
...
yjk
 , zt =

x1t
...
xnt
y1t
...
ymt

=
 xt
yt
 , (7.7)
Ar = diag[Ar1, . . . , Arn], Ac = diag[Ac1, . . . , Acm],
Ld = diag[Sd1 , . . . , S
d
n]− Sd, Lg = diag[Sg1 , . . . , Sgm]− Sg,
(7.8)
L =
Ar + αLd −A
−AT Ac + βLg
 , (7.9)
objective function (7.6) can be simplified as
Ok =
k∑
t=1
n∑
i=1
n∑
j=1
L11xitxjt +
k∑
t=1
m∑
i=1
m∑
j=1
L22yityjt − 2
k∑
t=1
n∑
i=1
m∑
j=1
aijxityjt
=
k∑
t=1
[xTt L
11xt + y
T
t L
22yt − 2xTt Ayt]
=
k∑
t=1
[xTt y
T
t ]
 L11 −A
−AT L22
xt
yt

=Tr(ZTLZ)
(7.10)
where Z = (z1, . . . , zk). Therefore, minimizing the objective function (4) with constraints (2) is equivalent
to minimize the following function
Qk = Tr(Z
TLZ) (7.11)
with constraints
ZTZ = XTX + Y TY = 2Ik (7.12)
According to [351], minimizing objective function (7.11) with constraints (7.12) can be solved by
Z∗ = (u0,u1, . . . ,uk−1) (7.13)
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where u0,u1, . . . ,uk−1 are k eigenvectors correspond to the k smallest eigenvalues of L. Meanwhile, the
smallest eigenvalue is 0, and entries in the corresponding eigenvector u0 are identical to each other, which
does not contribute to the calculation of the geodesic distance. Thus, let Zˆ denote the matrix by removing
the fist column of Z∗. The first n rows of Zˆ are the obtained (k−1)-dimensional representations of diseases,
and the rest m rows of Zˆ are the learned representations of genes. The geodesic distance between a disease
i and gene j can be calculated by
gdistij = ‖rˆi − qˆj‖2. (7.14)
7.2.2 Similarity network
Gene similarity
In this study, the learning process is regularized by similarity networks, and the similarities of genes are
calculated based on the Gene Ontology (GO). GO database provides a set of vocabularies to describe the
function of genes and gene products [125, 126]. The GO terms and their relationships are manifested as
a directed acyclic graph (DAG) where nodes represent terms while edges represent semantic relationships.
Many algorithms have been proposed to calculate the similarities of genes using ontology data, and the
approach proposed by [130] is used in this study.
Let DAGh = (Th, Eh) denote GO term h, where Th contains all the successor GO terms of h in the
DAG, and Eh contains the semantic relationships between h and other terms in Th. Each term t in Th has
a τ -value related to h: τh(t) = 1, if t = hτh(t) = max{we ∗ τh(t′)|t′ ∈ children of t}, otherwise (7.15)
where we is the weight of the edge (semantic relationships) in the DAG. Two types of semantic relationships
(“is a” and “part of ”) are used in the DAG, and the corresponding we is set to 0.8 and 0.6, respectively, as
recommended in [130].
Given DAGh = (Th, Eh) and DAGb = (Tb, Eb) for GO terms h and b, their similarity can be computed
by
sgo(h, b) =
∑
t∈Th∩Tb(τh(t) + τb(t))∑
t∈Th τh(t) +
∑
t∈Tb τb(t)
(7.16)
Then, the similarity of one GO term t
′
and a set of GO terms GO = {t1, t2, . . . , tl} is defined as
SGO(t
′
, GO) = max
1≤i≤l
(SGO(t
′
, ti)) (7.17)
Finally, the functional similarity of two genes g1 and g2 is calculated by
sgg1,g2 =
∑
1≤i≤n1 SGO(t1i, GO2) +
∑
1≤j≤n2 SGO(t2j , GO1)
n1 + n2
(7.18)
where GO1 = {t11, t12, . . . , t1n1} and GO2 = {t21, t22, . . . , t2n2} are two sets of GO terms that describe g1
and g2, respectively.
103
Disease similarity
The similarities among diseases are also calculated with the ontology data. Instead of GO, the Human
Phenotype Ontology (HPO) [127] is used to characterize human diseases. The HPO provides a vocabulary
of phenotypic terms related to human diseases. Each term represents a clinical abnormality, and all the
terms are structured as a DAG, in which every term is related to their parent terms by “is a” relationships.
Although diseases are not directly described by the HPO, the annotation file provided by HPO contains
terms associated with every disease, and thus Eq. 7.17, 7.18 can be used to compute the similarities of
diseases. When we calculate the similarities of phenotypic terms based on the DAG, we in Eq. 7.15 is set to
0.7 as recommended in [352].
7.2.3 Prior information
For diseases with only a few associated genes, the limited information would affect the performance of any
computational algorithms. This problem is especially serious for diseases with no known associated genes.
To solve this problem, we add some prior information for diseases with no known associations.
Specifically, given a disease i
′
, pi′ is added to the i
′
-th row of the matrix A as prior information so that
the shortage of known information can be alleviated. The j-th entry of pi′ is calculated by
pi′ j =
( n∑
i=1,i6=i′
sd
ii′aij
)
/
( n∑
i=1,i6=i′
aij
)
(7.19)
In our experiments, when cross-validation is used to evaluate the algorithm, the prior information is
added to the i-th row of matrix A as long as one of the associated genes of disease i is left to test the model.
Meanwhile, in the de novo study, prior information is also added to the diseases used for evaluation.
7.2.4 Data sources
The disease-gene association data are downloaded from the Online Mendelian Inheritance in Man (OMIM)
database [274] in August 2018. The Morbid Map at OMIM contains nearly seventy-five hundred entries
sorted alphabetically by disorder names. Each entry represents an association between a gene and a disease.
Different entries are labeled with different tags (‘(3)’, ‘[]’ and ‘?’) which indicate their reliabilities. To
obtain a reliable association dataset, based on [154], three steps were performed to preprocess the originally
downloaded data. First, entries with the tag ‘(3)’ are selected while others are abandoned. We adopt this
strategy because diseases with tag ‘(3)’ indicate that the molecular basis of these diseases is known and the
associations are reliable, while entries with ‘[]’ represent abnormal laboratory test values, and entries with ‘?’
represent provisional disease-gene associations. Second, disease entries are classified into distinct diseases by
merging disease subtypes based on their given disorder names. For instance, 17 entries of “Leigh syndrome”
are merged into disease “Leigh syndrome”, and the 19 complementary terms of “Lung cancer somatic” are
merged into “Lung Cancer”. Third, 74 diseases are removed because they are not annotated by any HPO
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terms. During the classification, string match was used to classify adjacent entries, followed by a manual
verification. Finally, we obtain a dataset consisting of 4,770 associations between 1,537 diseases and 3320
genes. Among the 1,537 diseases, 917 have only one associated gene (single-gene disease), while the rest
diseases have at least two associated genes (multiple-gene disease).
The ontology data of genes and phenotypes are downloaded from the GO database [125, 126], and the
HPO database [127], respectively. The PPI network used in the competing algorithms is downloaded from
the InWeb InBioMap database (version 2016 09 12) [170].
7.2.5 Evaluation metrics
In this study, the algorithm is evaluated in two steps. In the first step, our dgManifold is compared with two
competing algorithms: PCFM [7] and Katz [220]. PCFM is a matrix completion method which integrates
disease similarities and gene similarities to predict disease-gene associations. Katz is a classic network-based
method which uses Katz centrality to rank the disease-gene associations. We choose these two algorithms
because they are all multi-task algorithms which can predict all disease-gene associations as our dgManifold
does. The AUC (area under of the receiver operating characteristic (ROC) curve) scores calculated from
3-fold cross-validation are used to compare these three algorithms.
ROC curve plots the true positive rate [TP/(TP+FN)] verses the false positive rate [FP/(FP+TN)] at
different thresholds, and a larger AUC represents better overall performance. In this study, a true positive
(TP) is a known disease-gene association (positive sample) predicted as a disease-gene association, while a
false positive (FP) is a non-disease-gene association (negative sample) predicted as a disease-gene association.
A false negative (FN) is a positive sample predicted as negative while a true negative (TN) is a negative
sample predicted as negative. Since negative samples are not included in existing databases, we randomly
select a set of unknown disease-gene pairs as negative samples. The number of negative samples is equal to
that of positive samples. Considering that the selected negative samples may have small possibilities to be
a real disease-gene association, the random selection was run for five times to generate 5 sets of negative
samples. The final AUC score is the average score obtained from the 5 sets of samples.
During the cross-validation, the known disease-gene associations are split into 3 groups, and the algorithm
is run for 3 rounds. In each round, one group of associations is regarded as unknown (aij = 0), while the rest
two groups of associations are used to train the model. The prior information is recomputed during every
round of the cross-validation. Considering that single-gene diseases would have no known associated genes
if they are left for testing the model during the cross-validation, predicting disease genes for these diseases
is similar to predict disease genes for a completely new disease. Thus, the three algorithms are compared
on multiple-gene diseases and single-gene diseases separately. Additionally, to show the effect of the prior
information, the AUC scores of our method without prior information are also calculated.
In the second step, the model is trained with all the known associations, and the geodesic distance
between every unknown disease-gene pairs is calculated. To find out whether our new predictions are in
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concert with existing experimental studies, the top-10 predictions of two diseases, Lung Cancer and Bladder
Cancer, are searched from the existing literature. In our dataset, Lung Cancer has 16 associated genes, and
Bladder Cancer has 4 associated genes. We choose these two types of cancer because they are experimentally
well studied which could better prove our results.
7.3 Results
7.3.1 Model parameters
In our study, several parameters affect the performance of the model. To obtain the optimal parame-
ters, the grid search is conducted by searching k from {20, 30, 50, 100, 500, 800, 1000, 1200, 1500} and α from
{0, 0.01, 0.02, 0.05, 0.1, 0.2, 0.5}. β is set to be equal to α. The AUC score is used to determine whether
the selected parameters are optimal. Finally, for multiple-gene diseases, the model performs best when
k = 30, α = β = 0.2, and for single-gene diseases, the optimal parameters are k = 30, α = β = 0.1.
7.3.2 Cross-validation
Fig. 7.1 and Fig. 7.2 show the resulted ROC curves and AUC scores of the three competing algorithms
on multiple-gene diseases and single-gene diseases, respectively. For multiple-gene diseases, our dgManifold
achieves AUC score of 0.882 with prior information and 0.873 without prior information, while the AUC
scores of Katz and PCFM are 0.742 and 0.636, respectively. For single-gene diseases, the AUC score of our
dgManifold is 0.854 when prior information is used and 0.485 with no prior information, while the AUC
scores of Katz and PCFM are 0.455 and 0.322, respectively. These results show that our method is superior
to the competing methods in terms of the AUC scores.
It is worth noting that the AUC scores of all three algorithms are less than 0.5 when they are applied to
single-gene diseases. This is mainly because that single-gene diseases have no known associated genes during
the cross-validation, and algorithms can only use disease similarities and association data of other diseases
to perform the prediction. These data are not enough to generate accurate results, especially for supervised
algorithms. Thus, prior information is necessary for the algorithm. In fact, the results of our experiments
have shown that the prior information is beneficial to the prediction of disease-gene associations, especially
when the diseases have no known associated genes.
7.3.3 De novo study
In addition to AUC scores, we evaluate the performance of our dgManifold in predicting new disease-gene
associations. Specifically, Lung Cancer and Bladder Cancer are selected, and prior information corresponded
to these two diseases is added to matrix A. Then, all known disease-gene associations are used to train the
model (k = 30, α = β = 0.2), and the geodesic distance between all the unknown disease-gene pairs is
106
calculated. For each of the two selected diseases, the unknown disease-gene pairs are ranked based on the
geodesic distance in ascending order, and the top-10 predictions are searched from existing literature.
Table 7.1 shows the results of de novo studies. 5 out of 10 predicted genes have been experimentally
confirmed as associated with Lung Cancer. Among these genes, KCNK9 is a potential therapeutic target
[353]. HTRA1 contributes to the tumor formation by inhibiting the TGF-beta pathway [354]. ATP6AP1
and MYL2 are two potential biomarkers [355, 356]. Mutation of C282Y allele in HFE is associated with
Lung Cancer [357]. Although SEMA4A is not proved to be associated with Lung Cancer yet, it is related
to Lung Inflammation and Colorectal Cancer, and its role in Lung Cancer genesis might be discovered in
the future [358]. For Bladder Cancer, 3 out of 10 genes have been experimentally verified. Among them,
SMAD3 mediates epithelial-mesenchymal transition which affects the invasion and migration of Bladder
Cancer [359]. DMP1 is a tumor suppressor gene of Bladder Cancer [360]. CALR is potential biomarker
[361]. These results show that our predictions are in concert with existing reports, and thus our dgManifold
is valuable for predicting new disease-gene associations.
7.4 Conclusion
In this study, we have proposed dgManifold to predict disease-gene associations with manifold learning. Our
dgManifold assumes that the distance between diseases and their associated genes should be shorter than
that of other non-associated disease-gene pairs and maps the diseases and genes into a lower dimensional
manifold based on known disease-gene associations, disease similarity and gene similarity. The prediction of
new associations can be achieved by sorting the geodesic distance between unknown disease-gene pairs. The
cross-validation results show that our model outperforms the competing algorithms in terms of AUC scores
for both multiple-gene diseases and single-gene diseases. The further de novo studies also demonstrate that
our dgManifold is valuable in predicting new disease-gene associations.
Note that dgManifold is only regularized by disease similarities and gene similarities at the current version,
and the prior information is also obtained from the disease similarities. In the future, we can improve our
method by regularizing the objective function with more types of data and computing the prior information
with clinical evidences.
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Figure 7.1: ROC curves of the three competing algorithms on multiple-gene diseases.
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Figure 7.2: ROC curves of the three competing algorithms on single-gene diseases.
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Table 7.1: Top 10 predictions for lung cancer and bladder cancer
Gene symbol Reference
Lung Cancer
SEMA4A
KCNK9 [353]
MYL2 [356]
DENND5A
HTRA1 [354]
GABRA1
ATP6AP1 [355]
KCTD17
HFE [357]
BCS1L
Bladder Cancer
PDYN
DKC1
SMAD3 [359]
MCC
DMP1 [360]
MGP
CALR [361]
CASQ2
SOX18
GATM
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8Summary and future work
8.1 Summary
Disease-gene prediction is a critical yet challenging issue. The appropriate integration of multi-level biological
data is the key to improving prediction accuracy. This thesis aims at fusing multiples types of data with
multimodal deep learning to advance the performance of existing algorithms. In the meantime, several issues
that limit the accuracy of prediction are also addressed. In total, six objectives are proposed in Chapter 1,
and Chapters 2 to 7 have achieved these objectives.
Chapter 2 comprehensively reviews the computational algorithms for disease-gene prediction and achieves
Objective 1. Classic and state-of-the-art algorithms, databases and evaluation methods are summarized in
this chapter, and several future perspectives are discussed for designing new algorithms.
Chapter 3 designs a strategy to select negative data and applies the network energy-based model on both
a PPI network and a differential co-expression network to predict disease genes.
Chapter 4 first proposes an approach to construct sample-specific networks using static PPI network and
clinical gene expression data. Then, an ensemble strategy is used to predict disease genes from all the single
sample-based networks with centrality-based features.
Chapter 5 presents a method that uses node2vec to extract raw network embeddings from different
modalities (PPI networks and GO data in this study) and fuse them with multimodal DBN. The latent
representations learned by the model then significantly improve the prediction accuracy.
Chapter 6 presents a strategy to fuse raw features (mutation-based features) and similarity information
by a CNN model and use it to predict cancer driver genes.
Chapter 7 proposes an NMF-based method by using manifold learning to map diseases and genes onto
a lower-dimensional manifold. The mapping process is based on the known disease-gene associations and
regularized by disease similarities and gene similarities. After the mapping, the geodesic distance between
each disease-gene pair is used to prioritize disease genes.
With our proposed algorithms, the accuracy of computational disease gene prediction has been greatly
improved, and biochemists can combine the results of our prediction with their experiments to accelerate the
identification of disease genes. Meanwhile, the proposed models could be applied to other areas to enhance
the biological analysis. For instance, algorithms proposed in Chapters 5, 6 and 7 can be used to address
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linkage prediction problems, such as the prediction of protein interactions, drug-target associations, and
mRNA-disease associations, etc.
Note that our methods are not optimal. For instance, the algorithm proposed in Chapter 3 should combine
different expression with differential co-expression instead of only using the latter information. Hierarchical
clustering used in Chapter 4 should be compared with other algorithms to improve the clustering accuracy.
Dropout should be added to the models proposed in Chapters 5 and 6 to improve their stability. Therefore,
more efforts should be done to improve the performance of our algorithms in the future.
8.2 Future work
Based on the studies proposed in this thesis, several future directions for disease-gene prediction are proposed
as follows:
1. Using multi-omics data to predict disease genes.
Multi-omics data characterize different stages of cellular activities, and analyzing omic data is believed
to improve the accuracy of computational prediction. However, for disease gene prediction, most
algorithms still focus on genomic data, and only a few algorithms have used multi-omics data in their
studies [30]. Therefore, new methods should apply other omic data (transcriptomic, proteomic, etc.)
in their studies to discover the appropriate approaches to apply these data for disease-gene prediction.
2. Developing algorithms for personalized prediction.
Complex diseases might be associated with many disease genes; however, only a subset of malfunc-
tioning genes would lead to a disease, and the same disease on different patients might be caused
by different sets of genes. Therefore, predicting patient-specific disease genes should be useful for
personalized treatment. A previous study had used deep Boltzmann machine to predict personalized
mutations [362]. The results are promising, and the accuracy could be further improved with more
available samples.
3. Comparing the state-of-the-art methods, and developing a software package to implement these meth-
ods.
In Chapter 2, we address that many algorithms have not been applied in real disease-gene prediction
studies since they are not easy to use. Moreover, metrics alone cannot reveal the true prediction power
of an algorithm, and a comprehensive study should be conducted to address the performance of the
existing state-of-the-art methods. Therefore, a study should be proposed to compare the state-of-the-
art methods and implement the best ones by a user-friendly package or web tool.
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